<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" article-type="review-article">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2026.15940</article-id>
<article-id pub-id-type="publisher-id">OL-33-1-15940</article-id>
<article-categories>
<subj-group>
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Residual gastric cancer risk after <italic>Helicobacter pylori</italic> eradication: Mucosal immune trajectories (Review)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jian</given-names></name>
<xref rid="af1-ol-33-1-15940" ref-type="aff">1</xref>
<xref rid="fn1-ol-33-1-15940" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Tang</surname><given-names>Bolin</given-names></name>
<xref rid="af2-ol-33-1-15940" ref-type="aff">2</xref>
<xref rid="af3-ol-33-1-15940" ref-type="aff">3</xref>
<xref rid="fn1-ol-33-1-15940" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Li</given-names></name>
<xref rid="af1-ol-33-1-15940" ref-type="aff">1</xref>
<xref rid="c1-ol-33-1-15940" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-ol-33-1-15940"><label>1</label>Department of Laboratory Medicine, People&#x0027;s Hospital of Yuxi City, Yuxi, Yunnan 653100, P.R. China</aff>
<aff id="af2-ol-33-1-15940"><label>2</label>School of Public Health, Dali University, Dali, Yunnan 671000, P.R. China</aff>
<aff id="af3-ol-33-1-15940"><label>3</label>Research and Science Department, People&#x0027;s Hospital of Yuxi City, Yuxi, Yunnan 653100, P.R. China</aff>
<author-notes>
<corresp id="c1-ol-33-1-15940"><italic>Correspondence to</italic>: Professor Li Zhou, Department of Laboratory Medicine, People&#x0027;s Hospital of Yuxi City, 21 Nie&#x0027;er Road, Hongta, Yuxi, Yunnan 653100, P.R. China, E-mail: <email>zhouli2@kmmu.edu.cn</email></corresp>
<fn id="fn1-ol-33-1-15940"><label>&#x002A;</label><p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="collection"><month>01</month><year>2027</year></pub-date>
<pub-date pub-type="epub"><day>06</day><month>11</month><year>2026</year></pub-date>
<volume>33</volume>
<issue>1</issue>
<elocation-id>5</elocation-id>
<history>
<date date-type="received"><day>12</day><month>08</month><year>2026</year></date>
<date date-type="accepted"><day>20</day><month>10</month><year>2026</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Chen et al.</copyright-statement>
<copyright-year>2026</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p><italic>Helicobacter pylori</italic> is the leading modifiable cause of noncardia gastric cancer. Eradication lowers the incidence of primary and metachronous gastric neoplasia, yet a clinically meaningful risk remains once extensive atrophy, intestinal metaplasia or dysplasia is established. Current surveillance incorporates infection status and structural disease burden but does not directly assess biological recovery of the gastric mucosa. The present review examined whether mucosal immune trajectories after eradication are heterogeneous and whether localized immune measurements could explain variation in residual risk beyond morphology and epithelial-field alterations. Single-cell and spatial studies of human tissue have identified infection- and precursor-associated changes in myeloid differentiation, antigen presentation, T-cell states, metaplastic epithelium and stroma. Longitudinal evidence is less developed. Selected mucosal T-cell measurements support reversibility of specific responses, whereas gene-expression, histologic and microbiome trajectories provide molecular, structural or contextual evidence. Outcome-linked CD8-associated trajectories provide the closest currently available clinical-outcome immune evidence, but remain non-functional proxies derived from a post-resection population. A 2026 human single-cell study further identified persistent stromal and immunosuppressive niche features in post-eradication chronic atrophic gastritis, but did not provide paired longitudinal immune-function measurements or prospective neoplastic outcomes. Among the studies identified through the present search, none combined confirmation of eradication, paired measurements of immune function, concurrent assessment of the epithelial field and prospective dysplasia or cancer outcomes in individuals without previous gastric neoplasia. Therefore, the available evidence supports heterogeneous tissue recovery rather than a validated persistent immune state. Clinical translation would require reproducible functional immune activity, or a functionally validated proxy, together with independent outcome association, external validation and a clinically meaningful improvement in surveillance decisions beyond established histologic staging and lesion extent. Until such evidence is available, candidate immune markers should remain research tools and should not modify guideline-based surveillance.</p>
</abstract>
<kwd-group>
<kwd><italic>Helicobacter pylori</italic></kwd>
<kwd>gastric precursor lesions</kwd>
<kwd>residual gastric cancer risk</kwd>
<kwd>mucosal immune trajectories</kwd>
<kwd>risk stratification</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Yunnan Provincial Department of Science and Technology Kunming Medical University Special Projects</funding-source>
<award-id>202401AY070001-197</award-id>
</award-group>
<funding-statement>This review was supported by the Yunnan Provincial Department of Science and Technology Kunming Medical University Special Projects (grant no. 202401AY070001-197).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<label>1.</label>
<title>Introduction</title>
<p>Gastric cancer remains a major global health burden and a leading cause of cancer-related mortality, with a disproportionate incidence in East Asia and in selected regions of Latin America and Eastern Europe (<xref rid="b1-ol-33-1-15940" ref-type="bibr">1</xref>,<xref rid="b2-ol-33-1-15940" ref-type="bibr">2</xref>). <italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) is the predominant infectious cause of noncardia gastric cancer (<xref rid="b3-ol-33-1-15940" ref-type="bibr">3</xref>&#x2013;<xref rid="b8-ol-33-1-15940" ref-type="bibr">8</xref>). The Correa cascade describes progression from chronic active gastritis through atrophy, gastric intestinal metaplasia and dysplasia to invasive adenocarcinoma (<xref rid="b6-ol-33-1-15940" ref-type="bibr">6</xref>,<xref rid="b7-ol-33-1-15940" ref-type="bibr">7</xref>,<xref rid="b9-ol-33-1-15940" ref-type="bibr">9</xref>,<xref rid="b10-ol-33-1-15940" ref-type="bibr">10</xref>). Although this sequence remains clinically useful, it also exposes an important prevention gap, whereby current guidelines and syntheses of eradication studies distinguish microbiological cure from elimination of residual neoplastic risk (<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>&#x2013;<xref rid="b14-ol-33-1-15940" ref-type="bibr">14</xref>). Longitudinal studies further indicate that atrophy may improve after eradication, whereas intestinal metaplasia often persists or regresses only minimally over time (<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>,<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>). Therefore, clearance of the organism may precede, but does not ensure, restoration of a biologically equivalent gastric mucosa.</p>
<p>Eradication remains the cornerstone of gastric cancer prevention. The Maastricht VI/Florence consensus emphasizes that preventive benefit is greatest before advanced atrophy or intestinal metaplasia has developed (<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>). Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III) incorporates high-quality endoscopy, image enhancement, systematic biopsy, Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) staging and surveillance of advanced precursor lesions (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>). The 2025 American Gastroenterological Association Clinical Practice Update likewise recommends individualized screening and surveillance according to <italic>H. pylori</italic> status, family history, demographic risk, endoscopic findings and histology (<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>), while International Agency for Research on Cancer guidance extends screen-and-treat strategies to population-level prevention (<xref rid="b18-ol-33-1-15940" ref-type="bibr">18</xref>). These approaches address the initiating exposure and quantify structural risk, but provide limited insight into whether the mucosal tissue state has recovered biologically.</p>
<p>Randomized trials, cohort studies and systematic reviews consistently show lower rates of incident gastric cancer and metachronous neoplasia after eradication (<xref rid="b19-ol-33-1-15940" ref-type="bibr">19</xref>&#x2013;<xref rid="b23-ol-33-1-15940" ref-type="bibr">23</xref>). Earlier meta-analyses questioned the magnitude of benefit once intestinal metaplasia or dysplasia was present (<xref rid="b13-ol-33-1-15940" ref-type="bibr">13</xref>,<xref rid="b24-ol-33-1-15940" ref-type="bibr">24</xref>). Nevertheless, a 2025 synthesis of randomized trials reported risk reduction in these groups, although the effect estimates varied by region, duration of follow-up and study quality (<xref rid="b14-ol-33-1-15940" ref-type="bibr">14</xref>). Therefore, the remaining question is not whether eradication is beneficial, but whether residual risk is fully explained by persistent structural damage or whether additional tissue-level features convey independent information.</p>
<p>Against this background, the present review examined whether post-eradication mucosal immune trajectories add information beyond established measures of structural risk. Specifically, it distinguished candidate immune signals from residual inflammation, metaplastic architecture, epithelial-field alterations and exposure misclassification; separated biological persistence from clinical utility; and defined the longitudinal comparisons needed to support or refute the hypothesis.</p>
<p>The starting premise is that <italic>H. pylori</italic> eradication reduces the risk of primary and metachronous gastric neoplasia (<xref rid="b19-ol-33-1-15940" ref-type="bibr">19</xref>&#x2013;<xref rid="b23-ol-33-1-15940" ref-type="bibr">23</xref>), although effect estimates in established intestinal metaplasia or dysplasia differ across syntheses (<xref rid="b13-ol-33-1-15940" ref-type="bibr">13</xref>,<xref rid="b14-ol-33-1-15940" ref-type="bibr">14</xref>,<xref rid="b24-ol-33-1-15940" ref-type="bibr">24</xref>) and metaplastic tissue may persist (<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>,<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>). The working hypothesis is that a subset of eradicated patients may retain localized immune abnormalities that are not explained by active inflammation, morphologic burden or epithelial-field alterations. Such a signal would need to recur in anatomically matched samples, show functional relevance and retain information after competing tissue variables have been considered. Otherwise, it is more appropriately interpreted as residual infection-associated remodeling rather than a distinct clinically informative state.</p>
</sec>
<sec>
<label>2.</label>
<title>Literature search and evidence appraisal</title>
<sec>
<title/>
<sec>
<title>Literature identification</title>
<p>The present concept-driven narrative review evaluated a falsifiable translational proposition rather than estimating a pooled effect. Searches were updated through 1 July 2026 in PubMed/MEDLINE (<uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</uri>) and supplemented by Web of Science Core Collection (<uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</uri>) searches and forward and backward citation tracking. Search blocks covered <italic>H. pylori</italic> exposure and eradication; gastric atrophy, intestinal metaplasia, dysplasia and metachronous neoplasia; local immune responses, including tissue-resident memory T-cell (TRM) biology; single-cell and spatial methods; post-eradication tissue trajectories; and recent reviews of residual risk, oncogenic signaling and gastric immune tolerance. Study selection prioritized relevance to human gastric mucosa, longitudinal or paired designs, directness to the proposition under evaluation and explicit measurement of competing structural or epithelial fields. Animal models, organoids, established gastric cancer and other tumor types were included only as indirect mechanistic or methodological precedents.</p>
<p>No restriction was placed on the start date, and only English-language reports were considered. Foundational studies were retained when they established staging systems, pathogenetic concepts or metaplastic biology. As the present review was concept driven, no pooled effect estimate was calculated, and no formal risk-of-bias instrument was applied. Instead, each major inference was classified by disease stage, study design, population relevance, directness of evidence and the specific proposition it could support. Evidence was downgraded when it relied on cross-sectional sampling, post-resection populations, unvalidated proxies or mechanistic analogy. <xref rid="SD1-ol-33-1-15940" ref-type="supplementary-material">Table SI</xref> reports the search framework and selection principles, and <xref rid="SD1-ol-33-1-15940" ref-type="supplementary-material">Table SII</xref> provides a study-level appraisal of the directness and limitations of the evidence.</p>
</sec>
<sec>
<title>Evidence hierarchy and interpretive limits</title>
<p>The evidence base falls into the following four categories: i) Trials, cohorts and systematic reviews establish the residual-risk premise, with eradication reducing, but not eliminating, gastric cancer risk; ii) human tissue studies in gastritis, atrophy, intestinal metaplasia or dysplasia characterize remodeling associated with infection and precursor lesions; iii) paired post-eradication studies provide the most direct evidence of reversibility or persistence; and iv) findings from animals, organoids, established gastric cancer and other tumor types remain mechanistic analogies rather than evidence in gastric precursor tissue.</p>
<p>Evidence was weighted according to its directness to the claim rather than the sophistication of the technology used. Paired functional measurements in human tissue after confirmed eradication provide the strongest evidence for the central hypothesis. Molecular, histologic, microbiome and spatial measurements can reveal discordant recovery but remain contextual evidence or candidate proxies until linked to functional immune activity. Cross-sectional human atlases define states associated with infection or precursor lesions, whereas model systems and studies of established cancers identify mechanisms for subsequent testing. Confirmation would require verified exposure status, paired measurements of immune persistence and function, concurrent assessment of morphology and the epithelial field, and prospective dysplasia or gastric cancer outcomes in the same participants. Among the studies identified through the present search, none incorporated this complete evidentiary chain. Therefore, the available evidence supports infection-associated remodeling and heterogeneous recovery, while a durable, clinically meaningful immune state remains unproven, as summarized in <xref rid="tI-ol-33-1-15940" ref-type="table">Table I</xref>.</p>
</sec>
</sec>
</sec>
<sec>
<label>3.</label>
<title>Current clinical framework and its limits</title>
<p>Current risk stratification for gastric precursor lesions relies on endoscopic and histologic assessment. OLGA relates the extent and severity of atrophy to gastric cancer risk (<xref rid="b25-ol-33-1-15940" ref-type="bibr">25</xref>), whereas OLGIM uses intestinal metaplasia as a more reproducible surrogate (<xref rid="b26-ol-33-1-15940" ref-type="bibr">26</xref>). The updated Sydney System standardizes the grading of inflammation, activity, atrophy, intestinal metaplasia and <italic>H. pylori</italic> status (<xref rid="b27-ol-33-1-15940" ref-type="bibr">27</xref>). MAPS II and III translate these measures into surveillance recommendations (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b28-ol-33-1-15940" ref-type="bibr">28</xref>), and the Kyoto consensus classifies <italic>H. pylori</italic> gastritis as both an infectious disease and a precursor condition (<xref rid="b29-ol-33-1-15940" ref-type="bibr">29</xref>). Prospective surveillance data and endoscopic grading systems further support risk stratification of gastric precursor lesions (<xref rid="b30-ol-33-1-15940" ref-type="bibr">30</xref>,<xref rid="b31-ol-33-1-15940" ref-type="bibr">31</xref>), and their continued clinical use reflects their standardization, feasibility and established relevance.</p>
<p>The principal limitation of OLGA, OLGIM and Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) is one of scope, not validity. These systems quantify the extent and distribution of atrophy or intestinal metaplasia, yet patients within the same morphologic category may differ in host susceptibility and dietary exposure (<xref rid="b32-ol-33-1-15940" ref-type="bibr">32</xref>&#x2013;<xref rid="b34-ol-33-1-15940" ref-type="bibr">34</xref>). Infection history and gastric microbial ecology introduce further heterogeneity (<xref rid="b8-ol-33-1-15940" ref-type="bibr">8</xref>,<xref rid="b29-ol-33-1-15940" ref-type="bibr">29</xref>,<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>&#x2013;<xref rid="b39-ol-33-1-15940" ref-type="bibr">39</xref>). The relevant issue is whether tissue-level functional measures add risk information after established clinical and structural variables have been accounted for.</p>
<p><italic>H. pylori</italic>-driven carcinogenesis extends beyond direct epithelial injury. Adhesion, cytotoxin-associated gene A protein (CagA), vacuolating cytotoxin A (VacA), the <italic>cag</italic> type IV secretion system, urease activity, inflammatory signaling and disruption of epithelial polarity or &#x03B2;-catenin regulation all contribute to disease progression (<xref rid="b6-ol-33-1-15940" ref-type="bibr">6</xref>,<xref rid="b7-ol-33-1-15940" ref-type="bibr">7</xref>,<xref rid="b40-ol-33-1-15940" ref-type="bibr">40</xref>&#x2013;<xref rid="b46-ol-33-1-15940" ref-type="bibr">46</xref>). Experimental and translational studies implicate gastric stem-cell and regenerative programs in injury-associated epithelial remodeling and carcinogenesis (<xref rid="b10-ol-33-1-15940" ref-type="bibr">10</xref>,<xref rid="b47-ol-33-1-15940" ref-type="bibr">47</xref>&#x2013;<xref rid="b49-ol-33-1-15940" ref-type="bibr">49</xref>), while immune and inflammatory responses further shape the mucosal environment during persistent infection (<xref rid="b6-ol-33-1-15940" ref-type="bibr">6</xref>,<xref rid="b7-ol-33-1-15940" ref-type="bibr">7</xref>,<xref rid="b50-ol-33-1-15940" ref-type="bibr">50</xref>,<xref rid="b51-ol-33-1-15940" ref-type="bibr">51</xref>). Prospective human evidence also links <italic>H. pylori</italic> infection to the subsequent development of gastric cancer (<xref rid="b52-ol-33-1-15940" ref-type="bibr">52</xref>). Therefore, a precursor lesion is best viewed as a dynamically organized tissue system, although epithelial clones and metaplastic architecture may still account for a substantial proportion of residual risk.</p>
</sec>
<sec>
<label>4.</label>
<title>A falsifiable tissue-based framework</title>
<sec>
<title/>
<sec>
<title>Biological support: Localization, persistence and function</title>
<p>Post-eradication immune-associated remodeling is used in the present review as a provisional term for anatomically localized immune features detected after confirmed <italic>H. pylori</italic> eradication (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>&#x2013;<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>). It does not denote a disease entity, a clinical label or evidence of a causal contribution to residual risk. The epithelial field refers to metaplastic, clonal and epigenetic alterations distributed within mucosa at risk (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>&#x2013;<xref rid="b58-ol-33-1-15940" ref-type="bibr">58</xref>). For operational purposes, epithelial-field burden should be separated into structural and molecular components. The structural field should be represented, at minimum, by OLGIM stage, the anatomical extent and distribution of intestinal metaplasia assessed by EGGIM or systematically mapped histology, and metaplasia subtype, including the extent or proportion of incomplete-type metaplasia where available (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b26-ol-33-1-15940" ref-type="bibr">26</xref>,<xref rid="b27-ol-33-1-15940" ref-type="bibr">27</xref>,<xref rid="b31-ol-33-1-15940" ref-type="bibr">31</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). The molecular epithelial field comprises quantitatively assessed clonal/mutational and/or methylation burden in non-neoplastic mucosa (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). As no fixed methylation-marker panel has been validated specifically for post-eradication precursor mucosa (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>), marker selection should be prespecified and analytically validated rather than defined by an arbitrary numerical minimum (<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>). To qualify as a distinct immune-associated signal, a feature must be linked to previous exposure, localized to precursor-lesion mucosa or its surrounding field, reproducible after active inflammation and reinfection have been excluded, functionally relevant, and not explained by morphologic or epithelial-field burden.</p>
<p>Cell abundance alone cannot establish persistence (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>,<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>,<xref rid="b62-ol-33-1-15940" ref-type="bibr">62</xref>). More compelling evidence would require recurrence in anatomically matched paired tissue together with measurable functional immune activity, such as altered antigen presentation, myeloid function, T-cell persistence or <italic>ex vivo</italic> effector capacity (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>,<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>,<xref rid="b63-ol-33-1-15940" ref-type="bibr">63</xref>,<xref rid="b64-ol-33-1-15940" ref-type="bibr">64</xref>). Pathway-level and spatial measurements should remain candidate proxies until validated against function (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b62-ol-33-1-15940" ref-type="bibr">62</xref>).</p>
<p>Epithelial, stromal and microbial measurements provide essential context and competing explanations, but do not in themselves establish immune persistence (<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>,<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>&#x2013;<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). The greater the structural burden, the more important it becomes to show that an immune measurement contributes independent information (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b30-ol-33-1-15940" ref-type="bibr">30</xref>,<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>).</p>
</sec>
<sec>
<title>Clinical relevance: Independent prediction and utility</title>
<p>Clinical relevance requires more than biological persistence. A tissue feature must remain associated with prespecified dysplasia or gastric cancer outcomes after clinical, morphologic, infectious and epithelial-field variables have been considered (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b54-ol-33-1-15940" ref-type="bibr">54</xref>,<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>,<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>). The association should be replicated in external cohorts, and any improvement in risk stratification or surveillance decisions should provide sufficient clinical benefit to justify additional biopsies, assay costs and the potential harms of misclassification (<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>,<xref rid="b66-ol-33-1-15940" ref-type="bibr">66</xref>).</p>
<p>Causality and prediction should be evaluated separately. A persistent signal may be biologically genuine yet add little to clinical risk assessment, whereas a useful predictor does not need to be causal. Therefore, <xref rid="tII-ol-33-1-15940" ref-type="table">Table II</xref> distinguishes discovery-stage tissue features from clinically useful markers, which require a parsimonious assay, external validation and demonstrable clinical utility (<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>,<xref rid="b66-ol-33-1-15940" ref-type="bibr">66</xref>).</p>
</sec>
<sec>
<title>Relationship to trained immunity, tissue-resident memory and field effects</title>
<p>Trained immunity, tissue-resident memory and field cancerization describe different forms of biological persistence. Trained immunity refers to durable functional reprogramming of innate cells or their progenitors (<xref rid="b67-ol-33-1-15940" ref-type="bibr">67</xref>), TRM to antigen-experienced lymphocytes retained within tissue (<xref rid="b68-ol-33-1-15940" ref-type="bibr">68</xref>), and field cancerization to spatially distributed molecular alterations in epithelium at risk (<xref rid="b58-ol-33-1-15940" ref-type="bibr">58</xref>). Each provides a plausible precedent for incomplete biological normalization after <italic>H. pylori</italic> eradication, but none is equivalent to the immune-associated state considered in the present review.</p>
<p>A clinically relevant post-eradication immune signal would need to persist after confirmed eradication, demonstrate functional relevance, and retain outcome information after metaplastic, clonal and methylation fields have been considered. Tissue residence or mechanistic similarity alone is insufficient; these concepts are useful only insofar as they define testable comparisons involving exposure dependence, localization, persistence, function and residual outcome information.</p>
</sec>
<sec>
<title>Current evidence and unresolved questions</title>
<p>Recent high-resolution studies have documented infection-associated differences in the human gastric immune ecosystem. A 2025 study combining single-cell RNA sequencing with T-cell receptor analysis compared <italic>H. pylori</italic>-positive and <italic>H. pylori</italic>-negative gastric samples and identified reduced antigen presentation and phagocytic programs, altered monocyte-to-macrophage differentiation and attenuated T-cell states in infected tissue (<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>). A separate multi-omic survey of asymptomatic infection reported coordinated microbial and immune differences (<xref rid="b69-ol-33-1-15940" ref-type="bibr">69</xref>). These cross-sectional studies establish measurable remodeling during active infection, but neither included paired gastric mucosal biopsies obtained from the same individuals before and after H. pylori eradication.</p>
<p>Single-cell and spatial studies have resolved epithelial lineages, tissue organization and localized cell-cell interactions in gastritis and intestinal metaplasia (<xref rid="b62-ol-33-1-15940" ref-type="bibr">62</xref>,<xref rid="b70-ol-33-1-15940" ref-type="bibr">70</xref>&#x2013;<xref rid="b75-ol-33-1-15940" ref-type="bibr">75</xref>). Genomic and methylation studies have also identified clonal and epigenetic heterogeneity within intestinal metaplasia (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). These datasets generate candidate epithelial-immune relationships, but cannot determine whether an immune-associated feature persists after eradication.</p>
<p>More direct post-eradication tissue evidence has also emerged. A 2026 single-cell study of 22 human gastric antral mucosal samples spanning active infection and post-eradication chronic atrophic gastritis identified persistent immunomodulatory fibroblast states and an immunosuppressive stromal-epithelial niche after eradication (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>). This study moves beyond tumor-stage analogy by examining post-eradication precursor mucosa directly. However, its stage-stratified design did not provide anatomically paired longitudinal sampling, direct immune-function assays or prospective neoplastic outcomes.</p>
<p>Post-eradication studies indicate heterogeneous recovery across immune, molecular, structural, microbial, stromal and outcome-linked domains (<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>,<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>,<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>,<xref rid="b36-ol-33-1-15940" ref-type="bibr">36</xref>,<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>&#x2013;<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>,<xref rid="b76-ol-33-1-15940" ref-type="bibr">76</xref>). Ihan <italic>et al</italic> (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>) directly measured selected T-cell responses after eradication, whereas Kim <italic>et al</italic> (<xref rid="b54-ol-33-1-15940" ref-type="bibr">54</xref>) provided the closest currently available outcome-linked immune evidence through post-resection CD8-associated trajectories. The remaining studies primarily assessed gene expression, histology or microbial composition (<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>,<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>,<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>,<xref rid="b36-ol-33-1-15940" ref-type="bibr">36</xref>,<xref rid="b76-ol-33-1-15940" ref-type="bibr">76</xref>). Differences in population, sampling and outcome definition preclude an integrated causal inference. The beginning of section 7 and <xref rid="SD1-ol-33-1-15940" ref-type="supplementary-material">Table SII</xref> provide the study-level appraisal, and <xref rid="f1-ol-33-1-15940" ref-type="fig">Fig. 1</xref> summarizes the competing trajectories.</p>
</sec>
</sec>
</sec>
<sec>
<label>5.</label>
<title>Immune remodeling during chronic H. pylori infection</title>
<sec>
<title/>
<sec>
<title>Myeloid and antigen-presentation programs</title>
<p>Monocytes, macrophages, dendritic cells and neutrophils participate early in the gastric response to <italic>H. pylori</italic> (<xref rid="b50-ol-33-1-15940" ref-type="bibr">50</xref>). Single-cell data from infected human tissue show altered monocyte-to-macrophage differentiation and reduced phagocytic or antigen-presentation programs, while atlases of precursor lesions and established cancer reveal myeloid states that extend beyond conventional binary M1/M2 labels (<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>,<xref rid="b72-ol-33-1-15940" ref-type="bibr">72</xref>,<xref rid="b77-ol-33-1-15940" ref-type="bibr">77</xref>&#x2013;<xref rid="b79-ol-33-1-15940" ref-type="bibr">79</xref>). These observations establish heterogeneity during infection or in tumors, not persistence after eradication.</p>
<p>Studies of established gastric cancer have described secreted phosphoprotein 1 (SPP1)-positive macrophage-stromal interactions associated with matrix remodeling and immune suppression (<xref rid="b80-ol-33-1-15940" ref-type="bibr">80</xref>&#x2013;<xref rid="b82-ol-33-1-15940" ref-type="bibr">82</xref>). Within the present framework, these findings identify spatial relationships for testing in paired precursor tissue and do not define a precursor phenotype.</p>
<p>Therefore, post-eradication studies should prioritize anatomically matched measures of antigen-presentation capacity, phagocytic function and myeloid-T-cell or myeloid-stromal interactions rather than macrophage abundance or binary polarization labels. A credible precursor-lesion signal requires concordant functional evidence, or a proxy that has been validated against such evidence. Within the tissue-based framework, a post-eradication myeloid signal would be informative only if it persists in anatomically matched mucosa, retains functional abnormality and contributes information beyond structural and infectious explanations.</p>
</sec>
<sec>
<title>T-cell regulation and immune surveillance</title>
<p>Effective immune surveillance depends on a sequence of antigen capture, presentation, T-cell priming, clonal expansion and effector activity. Infection-stage data indicate that impaired antigen-presentation programs can coexist with altered T-cell states (<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>), but no study of precursor tissue has followed this coupled disturbance longitudinally after eradication.</p>
<p><italic>H. pylori</italic>-specific immunity includes protective, tolerogenic and tissue-damaging components. Human studies have identified <italic>H. pylori</italic>-specific regulatory T-cell and T helper 1 responses (<xref rid="b83-ol-33-1-15940" ref-type="bibr">83</xref>,<xref rid="b84-ol-33-1-15940" ref-type="bibr">84</xref>). Experimental models suggest that regulatory T cells, dendritic-cell-mediated regulatory T-cell skewing, &#x03B3;-glutamyl transpeptidase/VacA-dependent tolerance and inflammasome-related signaling influence microbial persistence and tissue injury (<xref rid="b85-ol-33-1-15940" ref-type="bibr">85</xref>&#x2013;<xref rid="b88-ol-33-1-15940" ref-type="bibr">88</xref>), while the interleukin (IL)-23/IL-17 axis provides an additional inflammatory pathway (<xref rid="b89-ol-33-1-15940" ref-type="bibr">89</xref>). The relevant question is not whether these programs operate during infection, but whether their balance is restored once the organism has been cleared.</p>
<p>TRMs provide a more specific candidate cellular substrate for localized immune persistence. Gastric <italic>H. pylori</italic>-specific CD8<sup>&#x002B;</sup> TRM populations have been characterized in humans and experimental models, including CagA-specific cells with antigen-specific effector activity (<xref rid="b63-ol-33-1-15940" ref-type="bibr">63</xref>). A 2025 human study further reported increased gastric mucosal CD8<sup>&#x002B;</sup> TRMs in <italic>H. pylori</italic>-infected subjects, recruitment through the C-X-C motif chemokine receptor 5/C-X-C motif chemokine ligand 13 axis and enhanced interferon-&#x03B3; (IFN-&#x03B3;) and tumor necrosis factor-&#x03B1; production (<xref rid="b90-ol-33-1-15940" ref-type="bibr">90</xref>). Experimental studies have demonstrated that CagA-specific gastric CD8&#x002B; TRMs contribute to controlling <italic>H. pylori</italic> during early infection (<xref rid="b63-ol-33-1-15940" ref-type="bibr">63</xref>), while a subsequent eradication and reinfection study showed that CagA-dependent Hobit&#x002B; gastric TRMs can persist long term and confer protection against reinfection (<xref rid="b91-ol-33-1-15940" ref-type="bibr">91</xref>). These findings establish biological plausibility for a durable resident T-cell compartment, but they do not demonstrate that functionally abnormal TRM populations persist after eradication in high-risk human precursor lesions or independently contribute to subsequent neoplasia.</p>
<p>Notably, an <italic>ex vivo</italic> single-cell analysis of a gastric intestinal metaplasia biopsy from one patient identified a resident-memory CD8<sup>&#x002B;</sup> T-cell cluster, providing direct precursor-stage evidence for the presence of a TRM compartment (<xref rid="b64-ol-33-1-15940" ref-type="bibr">64</xref>). However, this single-biopsy tissue-engineering study was designed to evaluate <italic>ex vivo</italic> cellular responses rather than longitudinal persistence after <italic>H. pylori</italic> eradication.</p>
<p>Therefore, within the present framework, TRM should be treated as a candidate substrate for persistence rather than evidence that persistence has occurred. Their relevance would require longitudinally matched assessment of residency-associated phenotype, antigen specificity or function after confirmed eradication, together with concurrent measurement of structural and epithelial-field burden. More broadly, T-cell phenotype or abundance becomes clinically informative only when persistent residency-associated or functional abnormalities are demonstrated after eradication and remain distinct from competing tissue-field explanations.</p>
</sec>
<sec>
<title>Exposure history and the gastric microbiome</title>
<p>Clinical records commonly reduce <italic>H. pylori</italic> status to positive, negative or eradicated. This simplification obscures distinctions among active infection, remote infection, time since eradication and reinfection, while antibiotic exposure, acid suppression and the diagnostic method can influence infection ascertainment or microbial measurements (<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b29-ol-33-1-15940" ref-type="bibr">29</xref>,<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>,<xref rid="b36-ol-33-1-15940" ref-type="bibr">36</xref>). Longitudinal human studies also suggest that microbial recovery is not uniform. In a randomized paired-biopsy study, eradication increased microbial diversity, but specific microbial patterns were associated with persistent inflammation, atrophy or intestinal metaplasia at one year (<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>). A 2026 longitudinal study of patients treated endoscopically for gastric cancer likewise identified substantial shifts in community structure after eradication (<xref rid="b36-ol-33-1-15940" ref-type="bibr">36</xref>). These findings position the microbiome as a contextual modifier and a competing explanation; neither demonstrates a persistent immune mechanism in precursor tissue from individuals without previous gastric neoplasia.</p>
<p>Therefore, exposure history should be reconstructed explicitly rather than represented by a binary category. Microbiome data should remain candidate modifiers until they show reproducible value independent of medication, diet, geography, infection status and morphologic disease (<xref rid="b8-ol-33-1-15940" ref-type="bibr">8</xref>,<xref rid="b34-ol-33-1-15940" ref-type="bibr">34</xref>&#x2013;<xref rid="b39-ol-33-1-15940" ref-type="bibr">39</xref>). Therefore, within the tissue-based framework, infection history and microbiome composition should be treated as mandatory competing variables and contextual modifiers rather than as evidence of persistent immune dysfunction themselves.</p>
</sec>
</sec>
</sec>
<sec>
<label>6.</label>
<title>Metaplastic and stromal substrates of persistence</title>
<sec>
<title/>
<sec>
<title>Gastric intestinal metaplasia and persistent tissue state</title>
<p>Gastric intestinal metaplasia is a plausible substrate for persistent tissue change as regenerative reprogramming, gland reconstruction, immune infiltration, stromal alteration and spatial heterogeneity coexist within the lesion (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>,<xref rid="b62-ol-33-1-15940" ref-type="bibr">62</xref>,<xref rid="b70-ol-33-1-15940" ref-type="bibr">70</xref>&#x2013;<xref rid="b75-ol-33-1-15940" ref-type="bibr">75</xref>). Spasmolytic polypeptide-expressing metaplasia models support continuity between injury and altered tissue architecture, but do not demonstrate immune persistence after eradication (<xref rid="b92-ol-33-1-15940" ref-type="bibr">92</xref>&#x2013;<xref rid="b96-ol-33-1-15940" ref-type="bibr">96</xref>).</p>
<p>Genomic, single-cell and methylation studies show that intestinal metaplasia contains distinct epithelial trajectories, clonal structures and subtype-specific methylation programs (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>,<xref rid="b74-ol-33-1-15940" ref-type="bibr">74</xref>,<xref rid="b75-ol-33-1-15940" ref-type="bibr">75</xref>). Therefore, any immune association must be evaluated after adjustment for the extent and subtype of metaplasia, dysplasia, OLGIM stage and epithelial-field burden.</p>
<p>The practical question is whether immune or stromal measurements retain risk information after these established structural variables have been considered. Until this has been demonstrated, a high-risk immune label would be premature.</p>
</sec>
<sec>
<title>Stromal-gland interactions and spatial organization</title>
<p>Across cancer biology, inflammation can remodel tissue through cytokine signaling, extracellular-matrix turnover, angiogenesis and regenerative programs (<xref rid="b97-ol-33-1-15940" ref-type="bibr">97</xref>,<xref rid="b98-ol-33-1-15940" ref-type="bibr">98</xref>). However, in gastric precursor mucosa, a putatively persistent immune mechanism must be demonstrated within the tissue architecture rather than inferred from transient inflammatory-cell counts.</p>
<p>Fibroblasts may link altered glands to immune-cell behavior. Direct post-eradication human evidence is available from a 2026 single-cell study of 22 human gastric antral mucosal samples spanning different stages of <italic>H. pylori</italic> infection and post-eradication chronic atrophic gastritis (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>). The study identified two subpopulations of immunomodulatory cancer-associated fibroblasts (iCAFs): Cellular communication network factor 2-expressing iCAF1 and Complement component 3-expressing iCAF3. These labels represent transcriptomically defined fibroblast subpopulations characterized by their respective marker-expression profiles. Both subpopulations remained detectable after eradication, particularly in patients without pathological improvement, and were associated with an immunosuppressive stromal-epithelial niche (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>). This study strengthens the case for stromal persistence in precursor mucosa, but its stage-stratified design lacked anatomically matched paired sampling and prospective neoplastic outcomes. Tumor-stage SPP1-positive macrophage-fibroblast networks remain mechanistic analogies rather than precursor-stage proof (<xref rid="b80-ol-33-1-15940" ref-type="bibr">80</xref>&#x2013;<xref rid="b82-ol-33-1-15940" ref-type="bibr">82</xref>).</p>
<p>Taken together, direct post-eradication human observations and tumor-stage studies identify plausible stromal-immune relationships, but only the former sample precursor mucosa after eradication. Establishing a persistent immune mechanism still requires anatomically standardized paired human tissue with functional validation. Therefore, <xref rid="f2-ol-33-1-15940" ref-type="fig">Fig. 2</xref> distinguishes observed post-eradication stromal remodeling from candidate immune-persistence relationships that still require longitudinal validation.</p>
</sec>
</sec>
</sec>
<sec>
<label>7.</label>
<title>Human evidence after eradication</title>
<sec>
<title/>
<sec>
<title>Directness, recovery heterogeneity and evidence ceiling</title>
<sec>
<title>Direct evidence of immune reversibility</title>
<p>The most direct longitudinal evidence of immune-function change after eradication comes from Ihan <italic>et al</italic> (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>). In 24 patients with duodenal ulcer, gastric mucosal T-cell CD25 expression and IFN-&#x03B3; production declined at 3 and 12 months after <italic>H. pylori</italic> eradication (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>). These findings demonstrate reversibility of selected infection-dependent T-cell responses. However, the study population did not have gastric precursor disease, and the immune environment of duodenal ulcers may differ substantially from that of extensive atrophy or intestinal metaplasia. Therefore, the observed reversibility cannot be assumed to generalize to high-risk precursor mucosa. The decline in CD25 expression and IFN-&#x03B3; production could theoretically reflect contraction or phenotypic remodeling of a tissue-resident T-cell compartment after removal of bacterial antigen, but the study did not phenotype residency-associated markers or distinguish resident from recirculating T cells. Therefore, TRM clearance cannot be inferred from these data. Only a restricted set of T-cell functions was examined, and neither epithelial-field burden nor subsequent neoplastic outcomes were assessed.</p>
</sec>
</sec>
<sec>
<title>Molecular and structural recovery</title>
<p>Paired molecular and structural studies show discordant tissue recovery, but do not directly establish persistent immune function. A randomized, placebo-controlled study examined 54 gastric biopsies from 27 participants and identified changes in gene expression one year after eradication, demonstrating molecular responsiveness in gastric precursor disease (<xref rid="b76-ol-33-1-15940" ref-type="bibr">76</xref>). Among 65 patients with intestinal metaplasia, 44 (67.7&#x0025;) retained metaplasia after a mean follow-up of 33.9 months, and persistence was associated with greater baseline nuclear &#x03B2;-catenin expression (<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>). In a prospective cohort of 172 patients followed histologically for up to 17 years, atrophy improved after eradication, whereas intestinal metaplasia did not change significantly at either biopsy site (<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>). Therefore, molecular or inflammatory improvement may coexist with structural persistence, a pattern that primarily supports epithelial and tissue-field explanations.</p>
</sec>
<sec>
<title>Outcome-linked and contextual evidence</title>
<p>Among the available studies, Kim <italic>et al</italic> (<xref rid="b54-ol-33-1-15940" ref-type="bibr">54</xref>) provide the closest currently available human evidence linking post-eradication immune remodeling to a clinical neoplastic outcome. In 36 patients who developed metachronous gastric neoplasia after eradication and 36 matched controls, post-eradication histologic and CD8-associated trajectories differed between outcome groups (<xref rid="b54-ol-33-1-15940" ref-type="bibr">54</xref>). This head-to-head comparison gives the study greater evidentiary weight than a purely cross-sectional immune association. Nevertheless, the measurements were immunohistochemical proxies rather than direct functional assays, and all participants had previously undergone endoscopic resection for gastric neoplasia, implying a pre-existing neoplastic epithelial and stromal field. Therefore, the study supports an outcome-associated immune trajectory but does not establish persistent immune dysfunction as an independent risk mechanism in a primary-prevention population. Separately, a 2026 single-cell study of 22 human antral mucosal samples spanning infected and post-eradication chronic atrophic gastritis identified persistent immunomodulatory fibroblast states and an immunosuppressive stromal-epithelial niche after eradication (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>). This provides direct post-eradication human tissue evidence of microenvironmental persistence, but not paired longitudinal immune-function evidence or prospective neoplastic outcome association. Microbial studies provide additional context, including a randomized cohort showing marked microbial remodeling at one year after eradication, with specific taxa associated with persistent inflammation, atrophy or intestinal metaplasia (<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>), and a 2026 post-resection cohort which showed non-uniform microbiome changes after eradication (<xref rid="b36-ol-33-1-15940" ref-type="bibr">36</xref>). These observations are contextual rather than functional immune evidence.</p>
</sec>
<sec>
<title>Overall interpretation of the human evidence</title>
<p>The evidence hierarchy is complementary rather than uniform. Ihan <italic>et al</italic> (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>) provide the most direct longitudinal evidence of selected immune-function reversibility, whereas Kim <italic>et al</italic> (<xref rid="b54-ol-33-1-15940" ref-type="bibr">54</xref>) provide the strongest currently available outcome-linked immune evidence. Neither study establishes a persistent, functionally defined immune state that independently predicts incident neoplasia in an eradicated primary-prevention population. Molecular, structural, microbial and stromal single-cell observations support heterogeneous recovery but arise from non-equivalent populations and biological domains. The 2026 post-eradication single-cell study increases the directness of tissue-persistence evidence, as it samples chronic atrophic gastritis after eradication, but does not complete the within-person functional-outcome chain (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>). Among eligible studies identified through the present search, none assessed immune persistence and function, epithelial-field burden and prospective incident outcomes in the same eradicated individuals without previous gastric neoplasia. Therefore, current human evidence supports heterogeneous recovery, but not an independent persistent immune state.</p>
</sec>
<sec>
<title>Post-eradication trajectories</title>
<p>A total of four longitudinal patterns are analytically useful. A normalizing trajectory denotes resolution of active inflammation and infection-dependent immune activation (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>,<xref rid="b76-ol-33-1-15940" ref-type="bibr">76</xref>). Structural persistence refers to retained atrophy or intestinal metaplasia (<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>,<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>); epithelial clonal and methylation fields should be treated as competing tissue-field explanations rather than assumed post-eradication trajectories (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). A persistently altered trajectory requires reproducible functional abnormalities, pathway-level changes or biologically validated spatial features after morphology and inflammation have been considered (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>&#x2013;<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>,<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>,<xref rid="b62-ol-33-1-15940" ref-type="bibr">62</xref>). Reinfection, inconsistent biopsy location, medication exposure, inadequate tissue or assay instability define an indeterminate trajectory (<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b27-ol-33-1-15940" ref-type="bibr">27</xref>,<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>,<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>). These are research constructs, not clinical labels.</p>
<p>The most informative confirmation cohort would include individuals with verified eradication, no previous gastric neoplasia and a guideline-defined high-risk precursor phenotype, such as OLGIM III&#x2013;IV or extensive endoscopic intestinal metaplasia (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b28-ol-33-1-15940" ref-type="bibr">28</xref>,<xref rid="b30-ol-33-1-15940" ref-type="bibr">30</xref>,<xref rid="b31-ol-33-1-15940" ref-type="bibr">31</xref>). The key comparison is not simply between infected and eradicated tissue, but between eradicated patients with and without reproducible immune abnormalities after concurrent assessment of morphology, epithelial-field burden, reinfection, medication exposure and sampling location. Post-resection cohorts remain valuable for secondary validation, but cannot replace primary-prevention evidence, as previous neoplasia implies a different epithelial and stromal field.</p>
</sec>
<sec>
<title>Falsification criteria</title>
<p>The hypothesis should be tested against explicit failure criteria. A candidate feature must recur in standardized paired biopsies after active inflammation, reinfection, medication effects and sampling variation have been addressed (<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b27-ol-33-1-15940" ref-type="bibr">27</xref>,<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>), and it must not simply track OLGIM stage, metaplasia extent, epithelial clone burden, biopsy site or baseline inflammation (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b26-ol-33-1-15940" ref-type="bibr">26</xref>,<xref rid="b27-ol-33-1-15940" ref-type="bibr">27</xref>,<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). A pathway-level or spatial proxy requires validation against functional immune activity and stage-appropriate outcomes (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>&#x2013;<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>,<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b62-ol-33-1-15940" ref-type="bibr">62</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>). Resolution after eradication (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>,<xref rid="b76-ol-33-1-15940" ref-type="bibr">76</xref>), inconsistent replication or absence of information beyond morphologic and epithelial-field measures (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>,<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>) would favor the more limited interpretation of infection-associated remodeling.</p>
</sec>
</sec>
</sec>
<sec>
<label>8.</label>
<title>Discussion</title>
<p>Taken together, the evidence supports a staged rather than a unitary interpretation. Eradication reduces primary and metachronous gastric neoplasia (<xref rid="b19-ol-33-1-15940" ref-type="bibr">19</xref>&#x2013;<xref rid="b23-ol-33-1-15940" ref-type="bibr">23</xref>) and reverses selected infection-dependent T-cell responses (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>), whereas structural and microbial abnormalities may persist (<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>,<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>,<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>,<xref rid="b36-ol-33-1-15940" ref-type="bibr">36</xref>). Clonal and epigenetic studies reveal additional heterogeneity within the epithelial field, but its trajectory after eradication remains unresolved (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). Among the studies identified through the present search, none provided longitudinal primary-prevention evidence that a persistent immune feature predicted incident neoplasia independently of structural and epithelial-field burden. Therefore, the remaining issues are the adequacy of competing explanations, the evidence needed for confirmation and the limits of clinical translation.</p>
<p>The present review organized the available evidence according to disease stage, directness and competing explanations rather than proposing a new disease label. Distinguishing remodeling during infection from persistence after eradication, and biological function from clinical utility, clarifies what is required before an immune-associated signal can be interpreted independently of structural disease, epithelial-field alterations or exposure misclassification.</p>
<sec>
<title/>
<sec>
<title>Competing explanations and comparative models</title>
<p>Residual risk may arise through several non-exclusive mechanisms. Metaplastic architecture may remain abnormal as gland identity and tissue organization reverse slowly, if at all. Clonal and methylation fields within intestinal metaplasia may account for outcome variation independently of immune measurements, although their persistence after eradication has not been established (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). Host susceptibility and dietary exposure may modify baseline risk (<xref rid="b32-ol-33-1-15940" ref-type="bibr">32</xref>&#x2013;<xref rid="b34-ol-33-1-15940" ref-type="bibr">34</xref>), while infection status and gastric microbial ecology may vary with eradication and geography (<xref rid="b8-ol-33-1-15940" ref-type="bibr">8</xref>,<xref rid="b29-ol-33-1-15940" ref-type="bibr">29</xref>,<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>&#x2013;<xref rid="b39-ol-33-1-15940" ref-type="bibr">39</xref>). Therefore, medication exposure, biopsy location and sampling quality should be recorded as design variables. A persistent immune signal may be biologically genuine yet remain secondary to a more influential structural or epithelial process.</p>
<p>The critical analytical test is whether mucosal immune measurements explain outcome variation after structural, epithelial, infectious and exposure-related alternatives have been incorporated adequately. Adding an immune panel to an incomplete baseline model would exaggerate its contribution. Therefore, <xref rid="tIII-ol-33-1-15940" ref-type="table">Table III</xref> treats competing explanations as obligatory comparators rather than peripheral caveats.</p>
<p>A clinically credible baseline model should cover four domains. Exposure assessment should reconstruct current or previous <italic>H. pylori</italic> infection, timing of eradication, reinfection, antibiotic use, acid suppression, diet and relevant host susceptibility (<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b29-ol-33-1-15940" ref-type="bibr">29</xref>,<xref rid="b32-ol-33-1-15940" ref-type="bibr">32</xref>&#x2013;<xref rid="b36-ol-33-1-15940" ref-type="bibr">36</xref>). Morphologic assessment should include high-quality endoscopy, Sydney-system pathology, OLGA/OLGIM stage, EGGIM where high-quality endoscopic mapping is available, the extent and anatomical distribution of metaplasia, metaplasia subtype and dysplasia (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b25-ol-33-1-15940" ref-type="bibr">25</xref>&#x2013;<xref rid="b31-ol-33-1-15940" ref-type="bibr">31</xref>). Therefore, a minimum structural epithelial-field core should include OLGIM stage, metaplasia extent/distribution and subtype. In molecularly profiled cohorts, at least one prespecified quantitative epithelial-field measure, such as methylation burden or clonal/mutational burden, should additionally be evaluated where tissue availability permits (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). Only then should a small prespecified set of immune-function measurements or functionally validated proxies be tested for added value.</p>
<p>Analysis should begin with the clinical, morphologic, exposure and epithelial-field model. Candidate immune markers can then be added to assess independent and incremental risk information. Prespecification, transparent reporting, calibration, external validation, risk-of-bias assessment and clinical utility should follow established principles for biomarkers and prediction models (<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>,<xref rid="b66-ol-33-1-15940" ref-type="bibr">66</xref>). Molecular subtypes defined in established gastric cancer (<xref rid="b99-ol-33-1-15940" ref-type="bibr">99</xref>,<xref rid="b100-ol-33-1-15940" ref-type="bibr">100</xref>) may suggest biological continuity but cannot substitute for measurements in precursor-lesion mucosa. Likewise, digital pathology is a measurement platform, not evidence that the proposed biological state exists.</p>
</sec>
<sec>
<title>Evidence required for confirmation and translation</title>
<p>Confirmation requires a longitudinal cohort of individuals without previous gastric neoplasia. Each participant should undergo verified assessment of eradication or reinfection, anatomically standardized paired sampling, and direct measurement of immune function or a functionally validated proxy. Morphology, epithelial-field burden and prospective dysplasia or gastric cancer outcomes should be assessed concurrently. Cross-study triangulation can justify further investigation but cannot replace this within-cohort chain. Sampling intervals, assays, candidate measurements and analytical plans should be prespecified and reported transparently (<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>). The corresponding measurement domains, limitations of the available direct evidence and key longitudinal tests are summarized in <xref rid="SD1-ol-33-1-15940" ref-type="supplementary-material">Table SIII</xref>. High-dimensional atlases and post-resection associations can identify candidate signals but cannot establish persistence or clinical relevance on their own.</p>
<p>Incident dysplasia or gastric cancer in individuals without previous gastric neoplasia should serve as the primary clinical endpoints, with metachronous neoplasia after endoscopic resection used for secondary validation. Biological persistence requires exposure linkage, localization and demonstrable function. Clinical utility additionally requires technical stability, external validation, calibration, incremental value and a measurable improvement in surveillance decisions (<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>,<xref rid="b66-ol-33-1-15940" ref-type="bibr">66</xref>). The longitudinal validation sequence integrating these requirements is summarized in <xref rid="f3-ol-33-1-15940" ref-type="fig">Fig. 3</xref>.</p>
</sec>
<sec>
<title>Clinical implications and application limits</title>
<p>At present, no tissue-based test derived from this framework is ready for routine use. Surveillance should continue to follow established recommendations and high-quality endoscopic and histologic assessment, and gastric dysplasia should be managed according to existing standards (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b28-ol-33-1-15940" ref-type="bibr">28</xref>,<xref rid="b101-ol-33-1-15940" ref-type="bibr">101</xref>,<xref rid="b102-ol-33-1-15940" ref-type="bibr">102</xref>). The immediate translational value lies in defining research-eligible populations rather than changing care. Patients with confirmed eradication and OLGIM III&#x2013;IV or extensive intestinal metaplasia should continue to be managed under current guidance, while candidate immune or spatial assays should be confined to prospective studies of individuals without previous gastric neoplasia and evaluated against incident dysplasia or cancer (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b28-ol-33-1-15940" ref-type="bibr">28</xref>,<xref rid="b30-ol-33-1-15940" ref-type="bibr">30</xref>,<xref rid="b31-ol-33-1-15940" ref-type="bibr">31</xref>).</p>
<p>Any viable assay must be parsimonious, reproducible across biopsy sites and compatible with routine pathology. Adoption would require sufficient clinical benefit to offset additional biopsies, cost, false reassurance and unnecessary endoscopy. Digital pathology may facilitate measurement, but its availability does not establish the existence of the proposed state or the clinical validity of a risk classifier.</p>
</sec>
<sec>
<title>Positioning relative to recent reviews</title>
<p>Recent reviews and perspectives have primarily addressed residual-risk management after eradication, infection-phase oncogenic signaling or immune tolerance in established gastric cancer (<xref rid="b103-ol-33-1-15940" ref-type="bibr">103</xref>&#x2013;<xref rid="b105-ol-33-1-15940" ref-type="bibr">105</xref>). The present review instead focuses on precursor-lesion mucosa after eradication in individuals without previous gastric neoplasia and asks whether paired immune measurements add information beyond structural and epithelial-field burden. This emphasis shifts the discussion from pathway cataloguing to directness of evidence, competing explanations, falsifiability and clinical increment.</p>
</sec>
<sec>
<title>Limitations and research priorities</title>
<p>The present review had several limitations. First, the integrated human evidence chain remains incomplete. Among eligible studies identified through the present search, none measured confirmed exposure, paired immune persistence and function, epithelial-field burden, incident cancer outcomes and incremental clinical value within the same prevention cohort. Available studies triangulate across non-equivalent populations and biological domains, and only selected T-cell measurements assess immune function directly. The incorporated TRM studies establish infection-stage biology, experimental durability or precursor-stage presence, but do not provide longitudinal evidence of abnormal TRM persistence after eradication in high-risk human precursor cohorts (<xref rid="b63-ol-33-1-15940" ref-type="bibr">63</xref>,<xref rid="b64-ol-33-1-15940" ref-type="bibr">64</xref>,<xref rid="b90-ol-33-1-15940" ref-type="bibr">90</xref>,<xref rid="b91-ol-33-1-15940" ref-type="bibr">91</xref>). The 2026 post-eradication single-cell study strengthens direct evidence of persistent stromal/immune-associated remodeling, but its stage-stratified design does not establish within-person persistence or clinical outcome independence (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>). Second, the concept-driven narrative design, restriction to English-language reports and reliance on published studies may introduce selection, availability and interpretive bias. Third, several proposed myeloid-stromal and spatial mechanisms still derive from established gastric cancer, animal models, organoids or other tumor types and cannot be assumed to operate in precursor mucosa after eradication (<xref rid="b47-ol-33-1-15940" ref-type="bibr">47</xref>,<xref rid="b48-ol-33-1-15940" ref-type="bibr">48</xref>,<xref rid="b77-ol-33-1-15940" ref-type="bibr">77</xref>,<xref rid="b80-ol-33-1-15940" ref-type="bibr">80</xref>&#x2013;<xref rid="b82-ol-33-1-15940" ref-type="bibr">82</xref>,<xref rid="b92-ol-33-1-15940" ref-type="bibr">92</xref>&#x2013;<xref rid="b96-ol-33-1-15940" ref-type="bibr">96</xref>,<xref rid="b106-ol-33-1-15940" ref-type="bibr">106</xref>).</p>
<p>The strongest outcome-linked immune observations were obtained in patients with previous gastric neoplasia (<xref rid="b54-ol-33-1-15940" ref-type="bibr">54</xref>), limiting generalizability to primary-prevention populations. Previous neoplasia also implies a different epithelial and stromal field, making these cohorts unsuitable as the sole basis for a marker intended for primary prevention. Even a reproducible mucosal immune state may prove clinically unusable because of sampling variation, platform dependence, cost, overfitting or a lack of incremental value.</p>
<p>The highest-priority next step is multicenter validation using paired biopsies from individuals without previous gastric neoplasia (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>&#x2013;<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>). Repeated assessment of eradication status and immune function should be interpreted alongside morphology, epithelial clonal or methylation burden and prospective outcomes in the same participants (<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>,<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>&#x2013;<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>). The decisive question is whether a parsimonious immune assay improves risk stratification or surveillance decisions beyond a complete clinical, morphologic, exposure and epithelial-field baseline (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>,<xref rid="b66-ol-33-1-15940" ref-type="bibr">66</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="conclusions">
<label>9.</label>
<title>Conclusions</title>
<p><italic>H. pylori</italic> eradication reduces gastric cancer risk but does not restore all high-risk gastric mucosa to a uniform biological state. Current human evidence supports heterogeneous post-eradication recovery, but does not yet establish a persistent, functionally defined immune state that predicts incident neoplasia independently of structural and epithelial-field burden. Therefore, the principal contribution of the present review is a falsifiable framework that separates immune persistence from residual inflammation, tissue-field damage and clinical utility. The immediate research priority is a prospective paired-biopsy cohort in individuals without previous gastric neoplasia that integrates verified eradication, immune function, epithelial-field measurements and incident outcomes. Until such evidence is available, candidate immune markers should remain investigational, and surveillance should continue to follow established endoscopic and histologic criteria.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="SD1-ol-33-1-15940" content-type="local-data">
<caption>
<title>Supporting Data</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data.pdf"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>JC and BT contributed to study conception, literature review, manuscript drafting and table organization. LZ and JC supervised the study design, revised key academic content and approved the final manuscript. All authors contributed to writing and revising the manuscript. All authors read and approved the final version of the manuscript. Data authentication is not applicable.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>EGGIM</term><def><p>Endoscopic Grading of Gastric Intestinal Metaplasia</p></def></def-item>
<def-item><term>OLGA</term><def><p>Operative Link on Gastritis Assessment</p></def></def-item>
<def-item><term>OLGIM</term><def><p>Operative Link on Gastric Intestinal Metaplasia Assessment</p></def></def-item>
<def-item><term>TRM</term><def><p>tissue-resident memory T cell</p></def></def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="b1-ol-33-1-15940"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><volume>74</volume><fpage>229</fpage><lpage>263</lpage><year>2024</year><pub-id pub-id-type="pmid">38572751</pub-id></element-citation></ref>
<ref id="b2-ol-33-1-15940"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>EC</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Grabsch</surname><given-names>HI</given-names></name><name><surname>van Grieken</surname><given-names>NCT</given-names></name><name><surname>Lordick</surname><given-names>F</given-names></name></person-group><article-title>Gastric cancer</article-title><source>Lancet</source><volume>396</volume><fpage>635</fpage><lpage>648</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31288-5</pub-id><pub-id pub-id-type="pmid">32861308</pub-id></element-citation></ref>
<ref id="b3-ol-33-1-15940"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Martel</surname><given-names>C</given-names></name><name><surname>Georges</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Clifford</surname><given-names>GM</given-names></name></person-group><article-title>Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis</article-title><source>Lancet Glob Health</source><volume>8</volume><fpage>e180</fpage><lpage>e190</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/S2214-109X(19)30488-7</pub-id><pub-id pub-id-type="pmid">31862245</pub-id></element-citation></ref>
<ref id="b4-ol-33-1-15940"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plummer</surname><given-names>M</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Vignat</surname><given-names>J</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>de Martel</surname><given-names>C</given-names></name></person-group><article-title>Global burden of gastric cancer attributable to <italic>Helicobacter pylori</italic></article-title><source>Int J Cancer</source><volume>136</volume><fpage>487</fpage><lpage>490</lpage><year>2015</year><pub-id pub-id-type="doi">10.1002/ijc.28999</pub-id><pub-id pub-id-type="pmid">24889903</pub-id></element-citation></ref>
<ref id="b5-ol-33-1-15940"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wroblewski</surname><given-names>LE</given-names></name><name><surname>Peek</surname><given-names>RM</given-names><suffix>Jr</suffix></name><name><surname>Wilson</surname><given-names>KT</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> and gastric cancer: Factors that modulate disease risk</article-title><source>Clin Microbiol Rev</source><volume>23</volume><fpage>713</fpage><lpage>739</lpage><year>2010</year><pub-id pub-id-type="doi">10.1128/CMR.00011-10</pub-id><pub-id pub-id-type="pmid">20930071</pub-id></element-citation></ref>
<ref id="b6-ol-33-1-15940"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amieva</surname><given-names>M</given-names></name><name><surname>Peek</surname><given-names>RM</given-names><suffix>Jr</suffix></name></person-group><article-title>Pathobiology of <italic>Helicobacter pylori</italic>-induced gastric cancer</article-title><source>Gastroenterology</source><volume>150</volume><fpage>64</fpage><lpage>78</lpage><year>2016</year><pub-id pub-id-type="doi">10.1053/j.gastro.2015.09.004</pub-id><pub-id pub-id-type="pmid">26385073</pub-id></element-citation></ref>
<ref id="b7-ol-33-1-15940"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polk</surname><given-names>DB</given-names></name><name><surname>Peek</surname><given-names>RM</given-names><suffix>Jr</suffix></name></person-group><article-title><italic>Helicobacter pylori</italic>: Gastric cancer and beyond</article-title><source>Nat Rev Cancer</source><volume>10</volume><fpage>403</fpage><lpage>414</lpage><year>2010</year><pub-id pub-id-type="doi">10.1038/nrc2857</pub-id><pub-id pub-id-type="pmid">20495574</pub-id></element-citation></ref>
<ref id="b8-ol-33-1-15940"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wizenty</surname><given-names>J</given-names></name><name><surname>Sigal</surname><given-names>M</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic>, microbiota and gastric cancer-principles of microorganism-driven carcinogenesis</article-title><source>Nat Rev Gastroenterol Hepatol</source><volume>22</volume><fpage>296</fpage><lpage>313</lpage><year>2025</year><pub-id pub-id-type="doi">10.1038/s41575-025-01042-2</pub-id><pub-id pub-id-type="pmid">40011753</pub-id></element-citation></ref>
<ref id="b9-ol-33-1-15940"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>P</given-names></name></person-group><article-title>Human gastric carcinogenesis: A multistep and multifactorial process-first American cancer society award lecture on cancer epidemiology and prevention</article-title><source>Cancer Res</source><volume>52</volume><fpage>6735</fpage><lpage>6740</lpage><year>1992</year><pub-id pub-id-type="pmid">1458460</pub-id></element-citation></ref>
<ref id="b10-ol-33-1-15940"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liabeuf</surname><given-names>D</given-names></name><name><surname>Oshima</surname><given-names>M</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>Sigal</surname><given-names>M</given-names></name></person-group><article-title>Stem cells, <italic>Helicobacter pylori</italic>, and mutational landscape: Utility of preclinical models to understand carcinogenesis and to direct management of gastric cancer</article-title><source>Gastroenterology</source><volume>162</volume><fpage>1067</fpage><lpage>1087</lpage><year>2022</year><pub-id pub-id-type="doi">10.1053/j.gastro.2021.12.252</pub-id><pub-id pub-id-type="pmid">34942172</pub-id></element-citation></ref>
<ref id="b11-ol-33-1-15940"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><name><surname>Rokkas</surname><given-names>T</given-names></name><name><surname>Gisbert</surname><given-names>JP</given-names></name><name><surname>Liou</surname><given-names>JM</given-names></name><name><surname>Schulz</surname><given-names>C</given-names></name><name><surname>Gasbarrini</surname><given-names>A</given-names></name><name><surname>Hunt</surname><given-names>RH</given-names></name><name><surname>Leja</surname><given-names>M</given-names></name><name><surname>O&#x0027;Morain</surname><given-names>C</given-names></name><etal/></person-group><article-title>Management of <italic>Helicobacter pylori</italic> infection: The Maastricht VI/Florence consensus report</article-title><source>Gut</source><volume>71</volume><fpage>1724</fpage><lpage>1762</lpage><year>2022</year><pub-id pub-id-type="doi">10.1136/gutjnl-2022-327745</pub-id><pub-id pub-id-type="pmid">35944925</pub-id></element-citation></ref>
<ref id="b12-ol-33-1-15940"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinis-Ribeiro</surname><given-names>M</given-names></name><name><surname>Lib&#x00E2;nio</surname><given-names>D</given-names></name><name><surname>Uchima</surname><given-names>H</given-names></name><name><surname>Spaander</surname><given-names>MCW</given-names></name><name><surname>Bornschein</surname><given-names>J</given-names></name><name><surname>Matysiak-Budnik</surname><given-names>T</given-names></name><name><surname>Tziatzios</surname><given-names>G</given-names></name><name><surname>Santos-Antunes</surname><given-names>J</given-names></name><name><surname>Areia</surname><given-names>M</given-names></name><name><surname>Chapelle</surname><given-names>N</given-names></name><etal/></person-group><article-title>Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European society of gastrointestinal endoscopy (ESGE), European Helicobacter and microbiota study group (EHMSG) and European society of pathology (ESP) guideline update 2025</article-title><source>Endoscopy</source><volume>57</volume><fpage>504</fpage><lpage>554</lpage><year>2025</year><pub-id pub-id-type="doi">10.1055/a-2529-5025</pub-id><pub-id pub-id-type="pmid">40112834</pub-id></element-citation></ref>
<ref id="b13-ol-33-1-15940"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HN</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>ZG</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: Evidence from a meta-analysis</article-title><source>Gastric Cancer</source><volume>19</volume><fpage>166</fpage><lpage>175</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s10120-015-0462-7</pub-id><pub-id pub-id-type="pmid">25609452</pub-id></element-citation></ref>
<ref id="b14-ol-33-1-15940"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Effect of <italic>Helicobacter pylori</italic> eradication on gastric cancer risk in patients with intestinal metaplasia or dysplasia: A meta-analysis of randomized controlled trials</article-title><source>Front Microbiol</source><volume>16</volume><fpage>1530549</fpage><year>2025</year><pub-id pub-id-type="doi">10.3389/fmicb.2025.1530549</pub-id><pub-id pub-id-type="pmid">40143868</pub-id></element-citation></ref>
<ref id="b15-ol-33-1-15940"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>KH</given-names></name><name><surname>Wu</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>HB</given-names></name><name><surname>Su</surname><given-names>LJ</given-names></name><name><surname>Sheu</surname><given-names>BS</given-names></name></person-group><article-title>Host Wnt/beta-catenin pathway triggered by <italic>Helicobacter pylori</italic> correlates with regression of gastric intestinal metaplasia after <italic>H. pylori</italic> eradication</article-title><source>J Med Microbiol</source><volume>58</volume><fpage>567</fpage><lpage>576</lpage><year>2009</year><pub-id pub-id-type="doi">10.1099/jmm.0.007310-0</pub-id><pub-id pub-id-type="pmid">19369517</pub-id></element-citation></ref>
<ref id="b16-ol-33-1-15940"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname><given-names>M</given-names></name><name><surname>Okimoto</surname><given-names>T</given-names></name><name><surname>Mizukami</surname><given-names>K</given-names></name><name><surname>Hirashita</surname><given-names>Y</given-names></name><name><surname>Wada</surname><given-names>Y</given-names></name><name><surname>Fukuda</surname><given-names>M</given-names></name><name><surname>Matsunari</surname><given-names>O</given-names></name><name><surname>Okamoto</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>R</given-names></name><name><surname>Fukuda</surname><given-names>K</given-names></name><etal/></person-group><article-title>Gastric mucosal changes, and sex differences therein, after <italic>Helicobacter pylori</italic> eradication: A long-term prospective follow-up study</article-title><source>J Gastroenterol Hepatol</source><volume>36</volume><fpage>2210</fpage><lpage>2216</lpage><year>2021</year><pub-id pub-id-type="doi">10.1111/jgh.15477</pub-id><pub-id pub-id-type="pmid">33656793</pub-id></element-citation></ref>
<ref id="b17-ol-33-1-15940"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>SC</given-names></name><name><surname>Wang</surname><given-names>AY</given-names></name><name><surname>Wallace</surname><given-names>MB</given-names></name><name><surname>Hwang</surname><given-names>JH</given-names></name></person-group><article-title>AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: Expert review</article-title><source>Gastroenterology</source><volume>168</volume><fpage>405</fpage><lpage>416.e1</lpage><year>2025</year><pub-id pub-id-type="doi">10.1053/j.gastro.2024.11.001</pub-id><pub-id pub-id-type="pmid">39718517</pub-id></element-citation></ref>
<ref id="b18-ol-33-1-15940"><label>18</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Park</surname><given-names>JY</given-names></name></person-group><article-title>Population-based <italic>Helicobacter pylori</italic> screen-and-treat strategies for gastric cancer prevention: Guidance on implementation</article-title><source>IARC Working Group Reports</source><publisher-loc>Lyon (FR)</publisher-loc><publisher-name>International Agency for Research on Cancer</publisher-name><year>2025</year></element-citation></ref>
<ref id="b19-ol-33-1-15940"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Chiang</surname><given-names>TH</given-names></name><name><surname>Chou</surname><given-names>CK</given-names></name><name><surname>Tu</surname><given-names>YK</given-names></name><name><surname>Liao</surname><given-names>WC</given-names></name><name><surname>Wu</surname><given-names>MS</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name></person-group><article-title>Association between <italic>Helicobacter pylori</italic> eradication and gastric cancer incidence: A systematic review and meta-analysis</article-title><source>Gastroenterology</source><volume>150</volume><fpage>1113</fpage><lpage>1124.e5</lpage><year>2016</year><pub-id pub-id-type="doi">10.1053/j.gastro.2016.01.028</pub-id><pub-id pub-id-type="pmid">26836587</pub-id></element-citation></ref>
<ref id="b20-ol-33-1-15940"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>AC</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Moayyedi</surname><given-names>P</given-names></name></person-group><article-title>Eradication therapy to prevent gastric cancer in <italic>Helicobacterpylori</italic>-positive individuals: Systematic review and meta-analysis of randomized controlled trials and observational studies</article-title><source>Gastroenterology</source><volume>169</volume><fpage>261</fpage><lpage>276</lpage><year>2025</year><pub-id pub-id-type="doi">10.1053/j.gastro.2024.12.033</pub-id><pub-id pub-id-type="pmid">39824392</pub-id></element-citation></ref>
<ref id="b21-ol-33-1-15940"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>IJ</given-names></name><name><surname>Kook</surname><given-names>MC</given-names></name><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Cho</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>CG</given-names></name><name><surname>Park</surname><given-names>B</given-names></name><name><surname>Nam</surname><given-names>BH</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> therapy for the prevention of metachronous gastric cancer</article-title><source>N Engl J Med</source><volume>378</volume><fpage>1085</fpage><lpage>1095</lpage><year>2018</year><pub-id pub-id-type="doi">10.1056/NEJMoa1708423</pub-id><pub-id pub-id-type="pmid">29562147</pub-id></element-citation></ref>
<ref id="b22-ol-33-1-15940"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>IJ</given-names></name><name><surname>Kim</surname><given-names>CG</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Kook</surname><given-names>MC</given-names></name><name><surname>Park</surname><given-names>B</given-names></name><name><surname>Joo</surname><given-names>J</given-names></name></person-group><article-title>Family history of gastric cancer and <italic>Helicobacter pylori</italic> treatment</article-title><source>N Engl J Med</source><volume>382</volume><fpage>427</fpage><lpage>436</lpage><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa1909666</pub-id><pub-id pub-id-type="pmid">31995688</pub-id></element-citation></ref>
<ref id="b23-ol-33-1-15940"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukase</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Uemura</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>S</given-names></name><name><surname>Terao</surname><given-names>S</given-names></name><name><surname>Amagai</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>Asaka</surname><given-names>M</given-names></name><collab collab-type="corp-author">Japan Gast Study Group</collab></person-group><article-title>Effect of eradication of <italic>Helicobacter pylori</italic> on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial</article-title><source>Lancet</source><volume>372</volume><fpage>392</fpage><lpage>397</lpage><year>2008</year><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61159-9</pub-id><pub-id pub-id-type="pmid">18675689</pub-id></element-citation></ref>
<ref id="b24-ol-33-1-15940"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rokkas</surname><given-names>T</given-names></name><name><surname>Rokka</surname><given-names>A</given-names></name><name><surname>Portincasa</surname><given-names>P</given-names></name></person-group><article-title>A systematic review and meta-analysis of the role of <italic>Helicobacter pylori</italic> eradication in preventing gastric cancer</article-title><source>Ann Gastroenterol</source><volume>30</volume><fpage>414</fpage><lpage>423</lpage><year>2017</year><pub-id pub-id-type="pmid">28655977</pub-id></element-citation></ref>
<ref id="b25-ol-33-1-15940"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rugge</surname><given-names>M</given-names></name><name><surname>Genta</surname><given-names>RM</given-names></name><name><surname>Fassan</surname><given-names>M</given-names></name><name><surname>Valentini</surname><given-names>E</given-names></name><name><surname>Coati</surname><given-names>I</given-names></name><name><surname>Guzzinati</surname><given-names>S</given-names></name><name><surname>Savarino</surname><given-names>E</given-names></name><name><surname>Zorzi</surname><given-names>M</given-names></name><name><surname>Farinati</surname><given-names>F</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name></person-group><article-title>OLGA gastritis staging for the prediction of gastric cancer risk: A long-term follow-up study of 7436 patients</article-title><source>Am J Gastroenterol</source><volume>113</volume><fpage>1621</fpage><lpage>1628</lpage><year>2018</year><pub-id pub-id-type="doi">10.1038/s41395-018-0353-8</pub-id><pub-id pub-id-type="pmid">30333540</pub-id></element-citation></ref>
<ref id="b26-ol-33-1-15940"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capelle</surname><given-names>LG</given-names></name><name><surname>de Vries</surname><given-names>AC</given-names></name><name><surname>Haringsma</surname><given-names>J</given-names></name><name><surname>Ter Borg</surname><given-names>F</given-names></name><name><surname>de Vries</surname><given-names>RA</given-names></name><name><surname>Bruno</surname><given-names>MJ</given-names></name><name><surname>van Dekken</surname><given-names>H</given-names></name><name><surname>Meijer</surname><given-names>J</given-names></name><name><surname>van Grieken</surname><given-names>NCT</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name></person-group><article-title>The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis</article-title><source>Gastrointest Endosc</source><volume>71</volume><fpage>1150</fpage><lpage>1158</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.gie.2009.12.029</pub-id><pub-id pub-id-type="pmid">20381801</pub-id></element-citation></ref>
<ref id="b27-ol-33-1-15940"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>MF</given-names></name><name><surname>Genta</surname><given-names>RM</given-names></name><name><surname>Yardley</surname><given-names>JH</given-names></name><name><surname>Correa</surname><given-names>P</given-names></name></person-group><article-title>Classification and grading of gastritis: The updated sydney system. International workshop on the histopathology of gastritis, houston 1994</article-title><source>Am J Surg Pathol</source><volume>20</volume><fpage>1161</fpage><lpage>1181</lpage><year>1996</year><pub-id pub-id-type="doi">10.1097/00000478-199610000-00001</pub-id><pub-id pub-id-type="pmid">8827022</pub-id></element-citation></ref>
<ref id="b28-ol-33-1-15940"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel-Nunes</surname><given-names>P</given-names></name><name><surname>Lib&#x00E2;nio</surname><given-names>D</given-names></name><name><surname>Marcos-Pinto</surname><given-names>R</given-names></name><name><surname>Areia</surname><given-names>M</given-names></name><name><surname>Leja</surname><given-names>M</given-names></name><name><surname>Esposito</surname><given-names>G</given-names></name><name><surname>Garrido</surname><given-names>M</given-names></name><name><surname>Kikuste</surname><given-names>I</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><name><surname>Matysiak-Budnik</surname><given-names>T</given-names></name><etal/></person-group><article-title>Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European society of gastrointestinal endoscopy (ESGE), European Helicobacter and microbiota study group (EHMSG), European society of pathology (ESP), and sociedade portuguesa de endoscopia digestiva (SPED) guideline update 2019</article-title><source>Endoscopy</source><volume>51</volume><fpage>365</fpage><lpage>388</lpage><year>2019</year><pub-id pub-id-type="pmid">30841008</pub-id></element-citation></ref>
<ref id="b29-ol-33-1-15940"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugano</surname><given-names>K</given-names></name><name><surname>Tack</surname><given-names>J</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>El-Omar</surname><given-names>EM</given-names></name><name><surname>Miura</surname><given-names>S</given-names></name><name><surname>Haruma</surname><given-names>K</given-names></name><name><surname>Asaka</surname><given-names>M</given-names></name><name><surname>Uemura</surname><given-names>N</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name><etal/></person-group><article-title>Kyoto global consensus report on <italic>Helicobacter pylori</italic> gastritis</article-title><source>Gut</source><volume>64</volume><fpage>1353</fpage><lpage>1367</lpage><year>2015</year><pub-id pub-id-type="doi">10.1136/gutjnl-2015-309252</pub-id><pub-id pub-id-type="pmid">26187502</pub-id></element-citation></ref>
<ref id="b30-ol-33-1-15940"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>den Hollander</surname><given-names>WJ</given-names></name><name><surname>Holster</surname><given-names>IL</given-names></name><name><surname>den Hoed</surname><given-names>CM</given-names></name><name><surname>Capelle</surname><given-names>LG</given-names></name><name><surname>Tang</surname><given-names>TJ</given-names></name><name><surname>Anten</surname><given-names>MP</given-names></name><name><surname>Prytz-Berset</surname><given-names>I</given-names></name><name><surname>Witteman</surname><given-names>EM</given-names></name><name><surname>ter Borg</surname><given-names>F</given-names></name><name><surname>Hartog</surname><given-names>G</given-names></name><etal/></person-group><article-title>Surveillance of premalignant gastric lesions: A multicentre prospective cohort study from low incidence regions</article-title><source>Gut</source><volume>68</volume><fpage>585</fpage><lpage>593</lpage><year>2019</year><pub-id pub-id-type="doi">10.1136/gutjnl-2017-314498</pub-id><pub-id pub-id-type="pmid">29875257</pub-id></element-citation></ref>
<ref id="b31-ol-33-1-15940"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcos</surname><given-names>P</given-names></name><name><surname>Brito-Gon&#x00E7;alves</surname><given-names>G</given-names></name><name><surname>Lib&#x00E2;nio</surname><given-names>D</given-names></name><name><surname>Pita</surname><given-names>I</given-names></name><name><surname>Castro</surname><given-names>R</given-names></name><name><surname>S&#x00E1;</surname><given-names>I</given-names></name><name><surname>Dinis-Ribeiro</surname><given-names>M</given-names></name><name><surname>Pimentel-Nunes</surname><given-names>P</given-names></name></person-group><article-title>Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: Can we replace histology assessment also in the west?</article-title><source>Gut</source><volume>69</volume><fpage>1762</fpage><lpage>1768</lpage><year>2020</year><pub-id pub-id-type="doi">10.1136/gutjnl-2019-320091</pub-id><pub-id pub-id-type="pmid">32051208</pub-id></element-citation></ref>
<ref id="b32-ol-33-1-15940"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Omar</surname><given-names>EM</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>Chow</surname><given-names>WH</given-names></name><name><surname>McColl</surname><given-names>KE</given-names></name><name><surname>Bream</surname><given-names>JH</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><name><surname>Herrera</surname><given-names>J</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>CC</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><etal/></person-group><article-title>Interleukin-1 polymorphisms associated with increased risk of gastric cancer</article-title><source>Nature</source><volume>404</volume><fpage>398</fpage><lpage>402</lpage><year>2000</year><pub-id pub-id-type="doi">10.1038/35006081</pub-id><pub-id pub-id-type="pmid">10746728</pub-id></element-citation></ref>
<ref id="b33-ol-33-1-15940"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x00E1;lez</surname><given-names>CA</given-names></name><name><surname>Sala</surname><given-names>N</given-names></name><name><surname>Capell&#x00E1;</surname><given-names>G</given-names></name></person-group><article-title>Genetic susceptibility and gastric cancer risk</article-title><source>Int J Cancer</source><volume>100</volume><fpage>249</fpage><lpage>260</lpage><year>2002</year><pub-id pub-id-type="doi">10.1002/ijc.10466</pub-id><pub-id pub-id-type="pmid">12115538</pub-id></element-citation></ref>
<ref id="b34-ol-33-1-15940"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsugane</surname><given-names>S</given-names></name><name><surname>Sasazuki</surname><given-names>S</given-names></name></person-group><article-title>Diet and the risk of gastric cancer: Review of epidemiological evidence</article-title><source>Gastric Cancer</source><volume>10</volume><fpage>75</fpage><lpage>83</lpage><year>2007</year><pub-id pub-id-type="doi">10.1007/s10120-007-0420-0</pub-id><pub-id pub-id-type="pmid">17577615</pub-id></element-citation></ref>
<ref id="b35-ol-33-1-15940"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>JJY</given-names></name><name><surname>Coker</surname><given-names>OO</given-names></name><name><surname>Chu</surname><given-names>E</given-names></name><name><surname>Szeto</surname><given-names>CH</given-names></name><name><surname>Luk</surname><given-names>STY</given-names></name><name><surname>Lau</surname><given-names>HCH</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after <italic>Helicobacter pylori</italic> eradication</article-title><source>Gut</source><volume>69</volume><fpage>1572</fpage><lpage>1580</lpage><year>2020</year><pub-id pub-id-type="doi">10.1136/gutjnl-2019-319826</pub-id><pub-id pub-id-type="pmid">31974133</pub-id></element-citation></ref>
<ref id="b36-ol-33-1-15940"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>CH</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Ha</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Shin</surname><given-names>CM</given-names></name><name><surname>Ahn</surname><given-names>S</given-names></name></person-group><article-title>Longitudinal remodeling of gastric microbiota following <italic>Helicobacter pylori</italic> eradication reveals an eradication-associated microbial signature in gastric cancer</article-title><source>Front Cell Infect Microbiol</source><volume>16</volume><fpage>1848437</fpage><year>2026</year><pub-id pub-id-type="doi">10.3389/fcimb.2026.1848437</pub-id><pub-id pub-id-type="pmid">42328161</pub-id></element-citation></ref>
<ref id="b37-ol-33-1-15940"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>RM</given-names></name><name><surname>Pereira-Marques</surname><given-names>J</given-names></name><name><surname>Pinto-Ribeiro</surname><given-names>I</given-names></name><name><surname>Costa</surname><given-names>JL</given-names></name><name><surname>Carneiro</surname><given-names>F</given-names></name><name><surname>Machado</surname><given-names>JC</given-names></name><name><surname>Figueiredo</surname><given-names>C</given-names></name></person-group><article-title>Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota</article-title><source>Gut</source><volume>67</volume><fpage>226</fpage><lpage>236</lpage><year>2018</year><pub-id pub-id-type="doi">10.1136/gutjnl-2017-314205</pub-id><pub-id pub-id-type="pmid">29102920</pub-id></element-citation></ref>
<ref id="b38-ol-33-1-15940"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coker</surname><given-names>OO</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Nakatsu</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>WKK</given-names></name><name><surname>Wong</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Sung</surname><given-names>JJY</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Mucosal microbiome dysbiosis in gastric carcinogenesis</article-title><source>Gut</source><volume>67</volume><fpage>1024</fpage><lpage>1032</lpage><year>2018</year><pub-id pub-id-type="doi">10.1136/gutjnl-2017-314281</pub-id><pub-id pub-id-type="pmid">28765474</pub-id></element-citation></ref>
<ref id="b39-ol-33-1-15940"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gantuya</surname><given-names>B</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Ajami</surname><given-names>NJ</given-names></name><name><surname>Oyuntsetseg</surname><given-names>K</given-names></name><name><surname>Azzaya</surname><given-names>D</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name></person-group><article-title>Gastric microbiota in <italic>Helicobacter pylori</italic>-negative and -positive gastritis among high incidence of gastric cancer area</article-title><source>Cancers (Basel)</source><volume>11</volume><fpage>504</fpage><year>2019</year><pub-id pub-id-type="doi">10.3390/cancers11040504</pub-id><pub-id pub-id-type="pmid">30974798</pub-id></element-citation></ref>
<ref id="b40-ol-33-1-15940"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>NR</given-names></name><name><surname>Hartung</surname><given-names>ML</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>A</given-names></name></person-group><article-title>Life in the human stomach: Persistence strategies of the bacterial pathogen <italic>Helicobacter pylori</italic></article-title><source>Nat Rev Microbiol</source><volume>11</volume><fpage>385</fpage><lpage>399</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/nrmicro3016</pub-id><pub-id pub-id-type="pmid">23652324</pub-id></element-citation></ref>
<ref id="b41-ol-33-1-15940"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backert</surname><given-names>S</given-names></name><name><surname>Tegtmeyer</surname><given-names>N</given-names></name><name><surname>Fischer</surname><given-names>W</given-names></name></person-group><article-title>Composition, structure and function of the <italic>Helicobacter pylori</italic> cag pathogenicity island encoded type IV secretion system</article-title><source>Future Microbiol</source><volume>10</volume><fpage>955</fpage><lpage>965</lpage><year>2015</year><pub-id pub-id-type="doi">10.2217/fmb.15.32</pub-id><pub-id pub-id-type="pmid">26059619</pub-id></element-citation></ref>
<ref id="b42-ol-33-1-15940"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatakeyama</surname><given-names>M</given-names></name></person-group><article-title>Oncogenic mechanisms of the <italic>Helicobacter pylori</italic> CagA protein</article-title><source>Nat Rev Cancer</source><volume>4</volume><fpage>688</fpage><lpage>694</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/nrc1433</pub-id><pub-id pub-id-type="pmid">15343275</pub-id></element-citation></ref>
<ref id="b43-ol-33-1-15940"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cover</surname><given-names>TL</given-names></name><name><surname>Blaser</surname><given-names>MJ</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> in health and disease</article-title><source>Gastroenterology</source><volume>136</volume><fpage>1863</fpage><lpage>1873</lpage><year>2009</year><pub-id pub-id-type="doi">10.1053/j.gastro.2009.01.073</pub-id><pub-id pub-id-type="pmid">19457415</pub-id></element-citation></ref>
<ref id="b44-ol-33-1-15940"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boquet</surname><given-names>P</given-names></name><name><surname>Ricci</surname><given-names>V</given-names></name></person-group><article-title>Intoxication strategy of <italic>Helicobacter pylori</italic> VacA toxin</article-title><source>Trends Microbiol</source><volume>20</volume><fpage>165</fpage><lpage>174</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.tim.2012.01.008</pub-id><pub-id pub-id-type="pmid">22364673</pub-id></element-citation></ref>
<ref id="b45-ol-33-1-15940"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>W</given-names></name></person-group><article-title>Assembly and molecular mode of action of the <italic>Helicobacter pylori</italic> Cag type IV secretion apparatus</article-title><source>FEBS J</source><volume>278</volume><fpage>1203</fpage><lpage>1212</lpage><year>2011</year><pub-id pub-id-type="doi">10.1111/j.1742-4658.2011.08036.x</pub-id><pub-id pub-id-type="pmid">21352490</pub-id></element-citation></ref>
<ref id="b46-ol-33-1-15940"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murata-Kamiya</surname><given-names>N</given-names></name><name><surname>Kurashima</surname><given-names>Y</given-names></name><name><surname>Teishikata</surname><given-names>Y</given-names></name><name><surname>Yamahashi</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Higashi</surname><given-names>H</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Akiyama</surname><given-names>T</given-names></name><name><surname>Peek</surname><given-names>RM</given-names><suffix>Jr</suffix></name><name><surname>Azuma</surname><given-names>T</given-names></name><name><surname>Hatakeyama</surname><given-names>TM</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells</article-title><source>Oncogene</source><volume>26</volume><fpage>4617</fpage><lpage>4626</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/sj.onc.1210251</pub-id><pub-id pub-id-type="pmid">17237808</pub-id></element-citation></ref>
<ref id="b47-ol-33-1-15940"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bess&#x00E8;de</surname><given-names>E</given-names></name><name><surname>Dubus</surname><given-names>P</given-names></name><name><surname>M&#x00E9;graud</surname><given-names>F</given-names></name><name><surname>Varon</surname><given-names>C</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> infection and stem cells at the origin of gastric cancer</article-title><source>Oncogene</source><volume>34</volume><fpage>2547</fpage><lpage>2555</lpage><year>2015</year><pub-id pub-id-type="doi">10.1038/onc.2014.187</pub-id><pub-id pub-id-type="pmid">25043305</pub-id></element-citation></ref>
<ref id="b48-ol-33-1-15940"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Fox</surname><given-names>JG</given-names></name><name><surname>Wang</surname><given-names>TC</given-names></name></person-group><article-title>The origins of gastric cancer from gastric stem cells: Lessons from mouse models</article-title><source>Cell Mol Gastroenterol Hepatol</source><volume>3</volume><fpage>331</fpage><lpage>338</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.jcmgh.2017.01.013</pub-id><pub-id pub-id-type="pmid">28462375</pub-id></element-citation></ref>
<ref id="b49-ol-33-1-15940"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houghton</surname><given-names>J</given-names></name><name><surname>Stoicov</surname><given-names>C</given-names></name><name><surname>Nomura</surname><given-names>S</given-names></name><name><surname>Rogers</surname><given-names>AB</given-names></name><name><surname>Carlson</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Fox</surname><given-names>JG</given-names></name><name><surname>Goldenring</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>TC</given-names></name></person-group><article-title>Gastric cancer originating from bone marrow-derived cells</article-title><source>Science</source><volume>306</volume><fpage>1568</fpage><lpage>1571</lpage><year>2004</year><pub-id pub-id-type="doi">10.1126/science.1099513</pub-id><pub-id pub-id-type="pmid">15567866</pub-id></element-citation></ref>
<ref id="b50-ol-33-1-15940"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusters</surname><given-names>JG</given-names></name><name><surname>van Vliet</surname><given-names>AHM</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name></person-group><article-title>Pathogenesis of <italic>Helicobacter pylori</italic> infection</article-title><source>Clin Microbiol Rev</source><volume>19</volume><fpage>449</fpage><lpage>490</lpage><year>2006</year><pub-id pub-id-type="doi">10.1128/CMR.00054-05</pub-id><pub-id pub-id-type="pmid">16847081</pub-id></element-citation></ref>
<ref id="b51-ol-33-1-15940"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peek</surname><given-names>RM</given-names><suffix>Jr</suffix></name><name><surname>Blaser</surname><given-names>MJ</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> and gastrointestinal tract adenocarcinomas</article-title><source>Nat Rev Cancer</source><volume>2</volume><fpage>28</fpage><lpage>37</lpage><year>2002</year><pub-id pub-id-type="doi">10.1038/nrc703</pub-id><pub-id pub-id-type="pmid">11902583</pub-id></element-citation></ref>
<ref id="b52-ol-33-1-15940"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uemura</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Matsumura</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Yamakido</surname><given-names>M</given-names></name><name><surname>Taniyama</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Schlemper</surname><given-names>RJ</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> infection and the development of gastric cancer</article-title><source>N Engl J Med</source><volume>345</volume><fpage>784</fpage><lpage>789</lpage><year>2001</year><pub-id pub-id-type="doi">10.1056/NEJMoa001999</pub-id><pub-id pub-id-type="pmid">11556297</pub-id></element-citation></ref>
<ref id="b53-ol-33-1-15940"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ihan</surname><given-names>A</given-names></name><name><surname>Tepez</surname><given-names>B</given-names></name><name><surname>Gubina</surname><given-names>M</given-names></name><name><surname>Malovrh</surname><given-names>T</given-names></name><name><surname>Kopitar</surname><given-names>A</given-names></name></person-group><article-title>Diminished interferon-gamma production in gastric mucosa T lymphocytes after <italic>H. pylori</italic> eradication in duodenal ulcer patients</article-title><source>Hepatogastroenterology</source><volume>46</volume><fpage>1740</fpage><lpage>1745</lpage><year>1999</year><pub-id pub-id-type="pmid">10430335</pub-id></element-citation></ref>
<ref id="b54-ol-33-1-15940"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Je</surname><given-names>Y</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name><name><surname>Youn</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Nahm</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> eradication is associated with a reduced risk of metachronous gastric neoplasia by restoring immune function in the gastric mucosa</article-title><source>Helicobacter</source><volume>30</volume><fpage>e70030</fpage><year>2025</year><pub-id pub-id-type="doi">10.1111/hel.70030</pub-id><pub-id pub-id-type="pmid">40169366</pub-id></element-citation></ref>
<ref id="b55-ol-33-1-15940"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><etal/></person-group><article-title><italic>Helicobacter pylori</italic>-induced inflammatory cancer transformation microenvironment drives gastric carcinogenesis</article-title><source>Cell Mol Gastroenterol Hepatol</source><volume>20</volume><fpage>101757</fpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.jcmgh.2026.101757</pub-id><pub-id pub-id-type="pmid">41759624</pub-id></element-citation></ref>
<ref id="b56-ol-33-1-15940"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>KK</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Chong</surname><given-names>RHH</given-names></name><name><surname>Uchihara</surname><given-names>T</given-names></name><name><surname>Lian</surname><given-names>BSX</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Sheng</surname><given-names>T</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Tay</surname><given-names>ST</given-names></name><name><surname>Sundar</surname><given-names>R</given-names></name><etal/></person-group><article-title>Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression</article-title><source>Cancer Cell</source><volume>41</volume><fpage>2019</fpage><lpage>2037.e8</lpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.ccell.2023.10.004</pub-id><pub-id pub-id-type="pmid">37890493</pub-id></element-citation></ref>
<ref id="b57-ol-33-1-15940"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>IH</given-names></name><name><surname>Park</surname><given-names>E</given-names></name><name><surname>Yoo</surname><given-names>M</given-names></name><name><surname>Yoon</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Myung</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>E</given-names></name><name><surname>Goldenring</surname><given-names>JR</given-names></name><name><surname>Jang</surname><given-names>B</given-names></name></person-group><article-title>Hybrid identity and distinct methylation profiles of incomplete intestinal metaplasia in the stomach</article-title><source>Gut</source><volume>75</volume><fpage>10</fpage><lpage>23</lpage><year>2026</year><pub-id pub-id-type="doi">10.1136/gutjnl-2025-335793</pub-id></element-citation></ref>
<ref id="b58-ol-33-1-15940"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtius</surname><given-names>K</given-names></name><name><surname>Wright</surname><given-names>NA</given-names></name><name><surname>Graham</surname><given-names>TA</given-names></name></person-group><article-title>An evolutionary perspective on field cancerization</article-title><source>Nat Rev Cancer</source><volume>18</volume><fpage>19</fpage><lpage>32</lpage><year>2018</year><pub-id pub-id-type="doi">10.1038/nrc.2017.102</pub-id><pub-id pub-id-type="pmid">29217838</pub-id></element-citation></ref>
<ref id="b59-ol-33-1-15940"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>GS</given-names></name><name><surname>Reitsma</surname><given-names>JB</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moons</surname><given-names>KGM</given-names></name></person-group><article-title>Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement</article-title><source>Ann Intern Med</source><volume>162</volume><fpage>55</fpage><lpage>63</lpage><year>2015</year><pub-id pub-id-type="doi">10.7326/L15-5093-2</pub-id><pub-id pub-id-type="pmid">25560714</pub-id></element-citation></ref>
<ref id="b60-ol-33-1-15940"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Sauerbrei</surname><given-names>W</given-names></name><name><surname>Taube</surname><given-names>SE</given-names></name><name><surname>Gion</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><collab collab-type="corp-author">Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics</collab></person-group><article-title>REporting recommendations for tumour MARKer prognostic studies (REMARK)</article-title><source>Br J Cancer</source><volume>93</volume><fpage>387</fpage><lpage>391</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/sj.bjc.6602678</pub-id><pub-id pub-id-type="pmid">16106245</pub-id></element-citation></ref>
<ref id="b61-ol-33-1-15940"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>ZM</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>ZY</given-names></name><name><surname>You</surname><given-names>LJ</given-names></name><name><surname>Zhai</surname><given-names>ZY</given-names></name><name><surname>Huang</surname><given-names>ZY</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing dissects the immunosuppressive signatures in <italic>Helicobacter pylori</italic>-infected human gastric ecosystem</article-title><source>Nat Commun</source><volume>16</volume><fpage>3903</fpage><year>2025</year><pub-id pub-id-type="doi">10.1038/s41467-025-59339-4</pub-id><pub-id pub-id-type="pmid">40281037</pub-id></element-citation></ref>
<ref id="b62-ol-33-1-15940"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>RJ</given-names></name><name><surname>Wichmann</surname><given-names>IA</given-names></name><name><surname>Su</surname><given-names>A</given-names></name><name><surname>Sathe</surname><given-names>A</given-names></name><name><surname>Shum</surname><given-names>MV</given-names></name><name><surname>Grimes</surname><given-names>SM</given-names></name><name><surname>Meka</surname><given-names>R</given-names></name><name><surname>Almeda</surname><given-names>A</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><etal/></person-group><article-title>A spatial transcriptomic signature of 26 genes resolved at single-cell resolution characterizes high-risk gastric cancer precursors</article-title><source>NPJ Precis Oncol</source><volume>9</volume><fpage>52</fpage><year>2025</year><pub-id pub-id-type="doi">10.1038/s41698-025-00816-w</pub-id><pub-id pub-id-type="pmid">40000871</pub-id></element-citation></ref>
<ref id="b63-ol-33-1-15940"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>MRA</given-names></name><name><surname>Gong</surname><given-names>R</given-names></name><name><surname>Friedrich</surname><given-names>V</given-names></name><name><surname>Engelsberger</surname><given-names>V</given-names></name><name><surname>Kretschmer</surname><given-names>L</given-names></name><name><surname>Wanisch</surname><given-names>A</given-names></name><name><surname>Jarosch</surname><given-names>S</given-names></name><name><surname>Ralser</surname><given-names>A</given-names></name><name><surname>Lugen</surname><given-names>B</given-names></name><name><surname>Quante</surname><given-names>M</given-names></name><etal/></person-group><article-title>CagA-specific gastric CD8<sup>&#x002B;</sup> tissue-resident T cells control <italic>Helicobacter pylori</italic> during the early infection phase</article-title><source>Gastroenterology</source><volume>164</volume><fpage>550</fpage><lpage>566</lpage><year>2023</year><pub-id pub-id-type="doi">10.1053/j.gastro.2022.12.016</pub-id><pub-id pub-id-type="pmid">36587707</pub-id></element-citation></ref>
<ref id="b64-ol-33-1-15940"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>AMK</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Colino-Sanguino</surname><given-names>Y</given-names></name><name><surname>Rodriguez de la Fuente</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>G</given-names></name><name><surname>Grimes</surname><given-names>SM</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>RJ</given-names></name><name><surname>Boyle</surname><given-names>ST</given-names></name><name><surname>Venhuizen</surname><given-names>J</given-names></name><etal/></person-group><article-title>ALTEN: A high-fidelity primary tissue-engineering platform to assess cellular responses ex vivo</article-title><source>Adv Sci (Weinh)</source><volume>9</volume><fpage>e2103332</fpage><year>2022</year><pub-id pub-id-type="doi">10.1002/advs.202103332</pub-id><pub-id pub-id-type="pmid">35611998</pub-id></element-citation></ref>
<ref id="b65-ol-33-1-15940"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>RF</given-names></name><name><surname>Moons</surname><given-names>KGM</given-names></name><name><surname>Riley</surname><given-names>RD</given-names></name><name><surname>Whiting</surname><given-names>PF</given-names></name><name><surname>Westwood</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>GS</given-names></name><name><surname>Reitsma</surname><given-names>JB</given-names></name><name><surname>Kleijnen</surname><given-names>J</given-names></name><name><surname>Mallett</surname><given-names>S</given-names></name><collab collab-type="corp-author">PROBAST Group&#x2020;</collab></person-group><article-title>PROBAST: A tool to assess the risk of bias and applicability of prediction model studies</article-title><source>Ann Intern Med</source><volume>170</volume><fpage>51</fpage><lpage>58</lpage><year>2019</year><pub-id pub-id-type="doi">10.7326/M18-1376</pub-id><pub-id pub-id-type="pmid">30596875</pub-id></element-citation></ref>
<ref id="b66-ol-33-1-15940"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vickers</surname><given-names>AJ</given-names></name><name><surname>Elkin</surname><given-names>EB</given-names></name></person-group><article-title>Decision curve analysis: A novel method for evaluating prediction models</article-title><source>Med Decis Making</source><volume>26</volume><fpage>565</fpage><lpage>574</lpage><year>2006</year><pub-id pub-id-type="doi">10.1177/0272989X06295361</pub-id><pub-id pub-id-type="pmid">17099194</pub-id></element-citation></ref>
<ref id="b67-ol-33-1-15940"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Dom&#x00ED;nguez-Andr&#x00E9;s</surname><given-names>J</given-names></name><name><surname>Barreiro</surname><given-names>LB</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name><name><surname>Fuchs</surname><given-names>E</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Mhlanga</surname><given-names>MM</given-names></name><name><surname>Mulder</surname><given-names>WJM</given-names></name><etal/></person-group><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nat Rev Immunol</source><volume>20</volume><fpage>375</fpage><lpage>388</lpage><year>2020</year><pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmid">32132681</pub-id></element-citation></ref>
<ref id="b68-ol-33-1-15940"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>PA</given-names></name><name><surname>Miron</surname><given-names>M</given-names></name><name><surname>Farber</surname><given-names>DL</given-names></name></person-group><article-title>Location, location, location: Tissue resident memory T cells in mice and humans</article-title><source>Sci Immunol</source><volume>4</volume><fpage>eaas9673</fpage><year>2019</year><pub-id pub-id-type="doi">10.1126/sciimmunol.aas9673</pub-id><pub-id pub-id-type="pmid">30952804</pub-id></element-citation></ref>
<ref id="b69-ol-33-1-15940"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorini</surname><given-names>C</given-names></name><name><surname>Tripathi</surname><given-names>KP</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Higdon</surname><given-names>SM</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Reinhardt</surname><given-names>A</given-names></name><name><surname>Kreslavsky</surname><given-names>T</given-names></name><name><surname>Thorell</surname><given-names>A</given-names></name><etal/></person-group><article-title>Metagenomic and single-cell RNA-Seq survey of the <italic>Helicobacter pylori</italic>-infected stomach in asymptomatic individuals</article-title><source>JCI Insight</source><volume>8</volume><fpage>e161042</fpage><year>2023</year><pub-id pub-id-type="doi">10.1172/jci.insight.161042</pub-id><pub-id pub-id-type="pmid">36810249</pub-id></element-citation></ref>
<ref id="b70-ol-33-1-15940"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Fei</surname><given-names>X</given-names></name><name><surname>Ke</surname><given-names>H</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with <italic>Helicobacter pylori</italic></article-title><source>J Adv Res</source><volume>74</volume><fpage>471</fpage><lpage>491</lpage><year>2025</year><pub-id pub-id-type="doi">10.1016/j.jare.2024.10.012</pub-id><pub-id pub-id-type="pmid">39414226</pub-id></element-citation></ref>
<ref id="b71-ol-33-1-15940"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowicki-Osuch</surname><given-names>K</given-names></name><name><surname>Zhuang</surname><given-names>L</given-names></name><name><surname>Cheung</surname><given-names>TS</given-names></name><name><surname>Black</surname><given-names>E</given-names></name><name><surname>Masqu&#x00E9;-Soler</surname><given-names>N</given-names></name><name><surname>Devonshire</surname><given-names>G</given-names></name><name><surname>Redmond</surname><given-names>A</given-names></name><name><surname>Freeman</surname><given-names>A</given-names></name><name><surname>di Pietro</surname><given-names>M</given-names></name><name><surname>Pilonis</surname><given-names>N</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing unifies developmental programs of esophageal and gastric intestinal metaplasia</article-title><source>Cancer Discov</source><volume>13</volume><fpage>1346</fpage><lpage>1363</lpage><year>2023</year><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0824</pub-id><pub-id pub-id-type="pmid">36929873</pub-id></element-citation></ref>
<ref id="b72-ol-33-1-15940"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Woo</surname><given-names>JK</given-names></name><name><surname>Seong</surname><given-names>JK</given-names></name><name><surname>Nam</surname><given-names>KT</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name></person-group><article-title>Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity</article-title><source>NPJ Precis Oncol</source><volume>6</volume><fpage>9</fpage><year>2022</year><pub-id pub-id-type="doi">10.1038/s41698-022-00251-1</pub-id><pub-id pub-id-type="pmid">35087207</pub-id></element-citation></ref>
<ref id="b73-ol-33-1-15940"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Yukun</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name></person-group><article-title>Integrated single-cell and spatial transcriptomics reveal the differentiation drivers of gastric epithelial lineage progression</article-title><source>Front Immunol</source><volume>17</volume><fpage>1712830</fpage><year>2026</year><pub-id pub-id-type="doi">10.3389/fimmu.2026.1712830</pub-id><pub-id pub-id-type="pmid">41737224</pub-id></element-citation></ref>
<ref id="b74-ol-33-1-15940"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Fei</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>A single-cell multi-omics atlas defines the cellular and molecular landscape of gastric intestinal metaplasia</article-title><source>J Transl Med</source><volume>24</volume><fpage>724</fpage><year>2026</year><pub-id pub-id-type="doi">10.1186/s12967-026-08150-w</pub-id><pub-id pub-id-type="pmid">42010673</pub-id></element-citation></ref>
<ref id="b75-ol-33-1-15940"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name></person-group><article-title>Dissecting the differentiation origins of intestinal metaplasia and early intestinal-type gastric cancer in gastric antrum by single-cell RNA profiling</article-title><source>NPJ Precis Oncol</source><volume>10</volume><fpage>167</fpage><year>2026</year><pub-id pub-id-type="doi">10.1038/s41698-026-01355-8</pub-id><pub-id pub-id-type="pmid">41807518</pub-id></element-citation></ref>
<ref id="b76-ol-33-1-15940"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>CJ</given-names></name><name><surname>Herrera-Goepfert</surname><given-names>R</given-names></name><name><surname>Tibshirani</surname><given-names>RJ</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Mohar</surname><given-names>A</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Parsonnet</surname><given-names>J</given-names></name></person-group><article-title>Changes of gene expression in gastric preneoplasia following <italic>Helicobacter pylori</italic> eradication therapy</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>15</volume><fpage>272</fpage><lpage>280</lpage><year>2006</year><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-05-0632</pub-id><pub-id pub-id-type="pmid">16492915</pub-id></element-citation></ref>
<ref id="b77-ol-33-1-15940"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Ramnarayanan</surname><given-names>K</given-names></name><name><surname>Sundar</surname><given-names>R</given-names></name><name><surname>Padmanabhan</surname><given-names>N</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Koiwa</surname><given-names>M</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Koh</surname><given-names>V</given-names></name><name><surname>Huang</surname><given-names>KK</given-names></name><name><surname>Tay</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Single-cell atlas of lineage states, tumor microenvironment and subtype-specific expression programs in gastric cancer</article-title><source>Cancer Discov</source><volume>12</volume><fpage>670</fpage><lpage>691</lpage><year>2022</year><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-0683</pub-id><pub-id pub-id-type="pmid">34642171</pub-id></element-citation></ref>
<ref id="b78-ol-33-1-15940"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Min</surname><given-names>M</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Ying</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing</article-title><source>Gut</source><volume>70</volume><fpage>464</fpage><lpage>475</lpage><year>2021</year><pub-id pub-id-type="doi">10.1136/gutjnl-2019-320368</pub-id><pub-id pub-id-type="pmid">32532891</pub-id></element-citation></ref>
<ref id="b79-ol-33-1-15940"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Allen</surname><given-names>JE</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Fisher</surname><given-names>EA</given-names></name><name><surname>Gilroy</surname><given-names>DW</given-names></name><name><surname>Goerdt</surname><given-names>S</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name><name><surname>Ivashkiv</surname><given-names>LB</given-names></name><name><surname>Lawrence</surname><given-names>T</given-names></name><etal/></person-group><article-title>Macrophage activation and polarization: Nomenclature and experimental guidelines</article-title><source>Immunity</source><volume>41</volume><fpage>14</fpage><lpage>20</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.008</pub-id><pub-id pub-id-type="pmid">25035950</pub-id></element-citation></ref>
<ref id="b80-ol-33-1-15940"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>SPP1&#x002B; macrophages and FAP&#x002B; fibroblasts promote the progression of pMMR gastric cancer</article-title><source>Sci Rep</source><volume>14</volume><fpage>26221</fpage><year>2024</year><pub-id pub-id-type="doi">10.1038/s41598-024-76298-w</pub-id><pub-id pub-id-type="pmid">39482333</pub-id></element-citation></ref>
<ref id="b81-ol-33-1-15940"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Fei</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Jiao</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Multi-omics analyses reveal interactions between GREM1&#x002B; fibroblasts and SPP1&#x002B; macrophages in gastric cancer</article-title><source>NPJ Precis Oncol</source><volume>9</volume><fpage>164</fpage><year>2025</year><pub-id pub-id-type="doi">10.1038/s41698-025-00967-w</pub-id><pub-id pub-id-type="pmid">40473882</pub-id></element-citation></ref>
<ref id="b82-ol-33-1-15940"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Identification of a stromal immunosuppressive barrier orchestrated by SPP1<sup>&#x002B;</sup>/C1QC<sup>&#x002B;</sup> macrophages and CD8<sup>&#x002B;</sup> exhausted T cells driving gastric cancer immunotherapy resistance</article-title><source>Front Immunol</source><volume>16</volume><fpage>1618591</fpage><year>2025</year><pub-id pub-id-type="doi">10.3389/fimmu.2025.1618591</pub-id><pub-id pub-id-type="pmid">40740771</pub-id></element-citation></ref>
<ref id="b83-ol-33-1-15940"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundgren</surname><given-names>A</given-names></name><name><surname>Suri-Payer</surname><given-names>E</given-names></name><name><surname>Enarsson</surname><given-names>K</given-names></name><name><surname>Svennerholm</surname><given-names>AM</given-names></name><name><surname>Lundin</surname><given-names>BS</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic>-specific CD4&#x002B; CD25high regulatory T cells suppress memory T-cell responses to <italic>H. pylori</italic> in infected individuals</article-title><source>Infect Immun</source><volume>71</volume><fpage>1755</fpage><lpage>1762</lpage><year>2003</year><pub-id pub-id-type="doi">10.1128/IAI.71.4.1755-1762.2003</pub-id><pub-id pub-id-type="pmid">12654789</pub-id></element-citation></ref>
<ref id="b84-ol-33-1-15940"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amedei</surname><given-names>A</given-names></name><name><surname>Cappon</surname><given-names>A</given-names></name><name><surname>Codolo</surname><given-names>G</given-names></name><name><surname>Cabrelle</surname><given-names>A</given-names></name><name><surname>Polenghi</surname><given-names>A</given-names></name><name><surname>Benagiano</surname><given-names>M</given-names></name><name><surname>Tasca</surname><given-names>E</given-names></name><name><surname>Azzurri</surname><given-names>A</given-names></name><name><surname>D&#x0027;Elios</surname><given-names>MM</given-names></name><name><surname>DelPrete</surname><given-names>G</given-names></name><name><surname>de Bernard</surname><given-names>M</given-names></name></person-group><article-title>The neutrophil-activating protein of <italic>Helicobacter pylori</italic> promotes Th1 immune responses</article-title><source>J Clin Invest</source><volume>116</volume><fpage>1092</fpage><lpage>1101</lpage><year>2006</year><pub-id pub-id-type="doi">10.1172/JCI27177</pub-id><pub-id pub-id-type="pmid">16543949</pub-id></element-citation></ref>
<ref id="b85-ol-33-1-15940"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rad</surname><given-names>R</given-names></name><name><surname>Brenner</surname><given-names>L</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Schwendy</surname><given-names>S</given-names></name><name><surname>Layland</surname><given-names>L</given-names></name><name><surname>da Costa</surname><given-names>CP</given-names></name><name><surname>Reindl</surname><given-names>W</given-names></name><name><surname>Dossumbekova</surname><given-names>A</given-names></name><name><surname>Friedrich</surname><given-names>M</given-names></name><name><surname>Saur</surname><given-names>D</given-names></name><etal/></person-group><article-title>CD25&#x002B;/Foxp3&#x002B; T cells regulate gastric inflammation and <italic>Helicobacter pylori</italic> colonization in vivo</article-title><source>Gastroenterology</source><volume>131</volume><fpage>525</fpage><lpage>537</lpage><year>2006</year><pub-id pub-id-type="doi">10.1053/j.gastro.2006.05.001</pub-id><pub-id pub-id-type="pmid">16890606</pub-id></element-citation></ref>
<ref id="b86-ol-33-1-15940"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>JY</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>MJ</given-names></name><name><surname>Mills</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Eaton</surname><given-names>KA</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Berndt</surname><given-names>BE</given-names></name><name><surname>Cole</surname><given-names>TS</given-names></name><etal/></person-group><article-title><italic>Helicobacter pylori</italic> immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice</article-title><source>Gastroenterology</source><volume>138</volume><fpage>1046</fpage><lpage>1054</lpage><year>2010</year><pub-id pub-id-type="doi">10.1053/j.gastro.2009.11.043</pub-id><pub-id pub-id-type="pmid">19931266</pub-id></element-citation></ref>
<ref id="b87-ol-33-1-15940"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oertli</surname><given-names>M</given-names></name><name><surname>Noben</surname><given-names>M</given-names></name><name><surname>Engler</surname><given-names>DB</given-names></name><name><surname>Semper</surname><given-names>RP</given-names></name><name><surname>Reuter</surname><given-names>S</given-names></name><name><surname>Maxeiner</surname><given-names>J</given-names></name><name><surname>Gerhard</surname><given-names>M</given-names></name><name><surname>Taube</surname><given-names>C</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>A</given-names></name></person-group><article-title><italic>Helicobacter pylori</italic> &#x03B3;-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance</article-title><source>Proc Natl Acad Sci USA</source><volume>110</volume><fpage>3047</fpage><lpage>3052</lpage><year>2013</year><pub-id pub-id-type="doi">10.1073/pnas.1211248110</pub-id><pub-id pub-id-type="pmid">23382221</pub-id></element-citation></ref>
<ref id="b88-ol-33-1-15940"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hitzler</surname><given-names>I</given-names></name><name><surname>Sayi</surname><given-names>A</given-names></name><name><surname>Kohler</surname><given-names>E</given-names></name><name><surname>Engler</surname><given-names>DB</given-names></name><name><surname>Koch</surname><given-names>KN</given-names></name><name><surname>Hardt</surname><given-names>WD</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>A</given-names></name></person-group><article-title>Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1&#x03B2; and IL-18</article-title><source>J Immunol</source><volume>188</volume><fpage>3594</fpage><lpage>3602</lpage><year>2012</year><pub-id pub-id-type="doi">10.4049/jimmunol.1103212</pub-id><pub-id pub-id-type="pmid">22403439</pub-id></element-citation></ref>
<ref id="b89-ol-33-1-15940"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>R</given-names></name><name><surname>Pallone</surname><given-names>F</given-names></name><name><surname>Monteleone</surname><given-names>G</given-names></name></person-group><article-title>Emerging role of IL-23/IL-17 axis in H pylori-associated pathology</article-title><source>World J Gastroenterol</source><volume>13</volume><fpage>5547</fpage><lpage>5551</lpage><year>2007</year><pub-id pub-id-type="doi">10.3748/wjg.v13.i42.5547</pub-id><pub-id pub-id-type="pmid">17948927</pub-id></element-citation></ref>
<ref id="b90-ol-33-1-15940"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ning</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name></person-group><article-title>Gastric mucosal CD8<sup>&#x002B;</sup>TRM cells are recruited through CXCR5-CXCL13 axis in <italic>Helicobacter pylori</italic> infected subjects</article-title><source>Cytokine</source><volume>190</volume><fpage>156904</fpage><year>2025</year><pub-id pub-id-type="doi">10.1016/j.cyto.2025.156904</pub-id><pub-id pub-id-type="pmid">40088523</pub-id></element-citation></ref>
<ref id="b91-ol-33-1-15940"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Ralser</surname><given-names>A</given-names></name><name><surname>Friedrich</surname><given-names>V</given-names></name><name><surname>Mibus</surname><given-names>C</given-names></name><name><surname>Engelsberger</surname><given-names>V</given-names></name><name><surname>Koch</surname><given-names>MRA</given-names></name><name><surname>Skerhut</surname><given-names>M</given-names></name><name><surname>Giese</surname><given-names>T</given-names></name><name><surname>Andr&#x00E4;</surname><given-names>I</given-names></name><etal/></person-group><article-title>CagA-dependent Hobit<sup>&#x002B;</sup> gastric tissue-resident memory T cells confer full protection from <italic>Helicobacter pylori</italic> reinfection</article-title><source>Gut</source><volume>74</volume><fpage>1792</fpage><lpage>1803</lpage><year>2025</year><pub-id pub-id-type="doi">10.1136/gutjnl-2025-334781</pub-id><pub-id pub-id-type="pmid">40473399</pub-id></element-citation></ref>
<ref id="b92-ol-33-1-15940"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bockerstett</surname><given-names>KA</given-names></name><name><surname>Lewis</surname><given-names>SA</given-names></name><name><surname>Noto</surname><given-names>CN</given-names></name><name><surname>Ford</surname><given-names>EL</given-names></name><name><surname>Saenz</surname><given-names>JB</given-names></name><name><surname>Jackson</surname><given-names>NM</given-names></name><name><surname>Ahn</surname><given-names>TH</given-names></name><name><surname>Mills</surname><given-names>JC</given-names></name><name><surname>DiPaolo</surname><given-names>RJ</given-names></name></person-group><article-title>Single- cell transcriptional analyses identify lineage-specific epithelial responses to inflammation and metaplastic development in the gastric corpus</article-title><source>Gastroenterology</source><volume>159</volume><fpage>2116</fpage><lpage>2129.e4</lpage><year>2020</year><pub-id pub-id-type="doi">10.1053/j.gastro.2020.08.027</pub-id><pub-id pub-id-type="pmid">32835664</pub-id></element-citation></ref>
<ref id="b93-ol-33-1-15940"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>CP</given-names></name><name><surname>Mills</surname><given-names>JC</given-names></name><name><surname>Goldenring</surname><given-names>JR</given-names></name></person-group><article-title>Murine models of gastric corpus preneoplasia</article-title><source>Cell Mol Gastroenterol Hepatol</source><volume>3</volume><fpage>11</fpage><lpage>26</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.jcmgh.2016.11.001</pub-id><pub-id pub-id-type="pmid">28174755</pub-id></element-citation></ref>
<ref id="b94-ol-33-1-15940"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>KT</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Sousa</surname><given-names>JF</given-names></name><name><surname>Weis</surname><given-names>VG</given-names></name><name><surname>O&#x0027;Neal</surname><given-names>RL</given-names></name><name><surname>Finke</surname><given-names>PE</given-names></name><name><surname>Romero-Gallo</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>G</given-names></name><name><surname>Mills</surname><given-names>JC</given-names></name><name><surname>Peek</surname><given-names>RM</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Mature chief cells are cryptic progenitors for metaplasia in the stomach</article-title><source>Gastroenterology</source><volume>139</volume><fpage>2028</fpage><lpage>2037.e9</lpage><year>2010</year><pub-id pub-id-type="doi">10.1053/j.gastro.2010.09.005</pub-id><pub-id pub-id-type="pmid">20854822</pub-id></element-citation></ref>
<ref id="b95-ol-33-1-15940"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldenring</surname><given-names>JR</given-names></name><name><surname>Nam</surname><given-names>KT</given-names></name></person-group><article-title>Oxyntic atrophy, metaplasia, and gastric cancer</article-title><source>Prog Mol Biol Transl Sci</source><volume>96</volume><fpage>117</fpage><lpage>131</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/B978-0-12-381280-3.00005-1</pub-id><pub-id pub-id-type="pmid">21075342</pub-id></element-citation></ref>
<ref id="b96-ol-33-1-15940"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>JC</given-names></name><name><surname>Goldenring</surname><given-names>JR</given-names></name></person-group><article-title>Metaplasia in the stomach arises from gastric chief cells</article-title><source>Cell Mol Gastroenterol Hepatol</source><volume>4</volume><fpage>85</fpage><lpage>88</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.jcmgh.2017.03.006</pub-id><pub-id pub-id-type="pmid">28560292</pub-id></element-citation></ref>
<ref id="b97-ol-33-1-15940"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Inflammation and cancer</article-title><source>Nature</source><volume>420</volume><fpage>860</fpage><lpage>867</lpage><year>2002</year><pub-id pub-id-type="doi">10.1038/nature01322</pub-id><pub-id pub-id-type="pmid">12490959</pub-id></element-citation></ref>
<ref id="b98-ol-33-1-15940"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Allavena</surname><given-names>P</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Balkwill</surname><given-names>F</given-names></name></person-group><article-title>Cancer-related inflammation</article-title><source>Nature</source><volume>454</volume><fpage>436</fpage><lpage>444</lpage><year>2008</year><pub-id pub-id-type="doi">10.1038/nature07205</pub-id><pub-id pub-id-type="pmid">18650914</pub-id></element-citation></ref>
<ref id="b99-ol-33-1-15940"><label>99</label><element-citation publication-type="journal"><collab collab-type="corp-author">Cancer Genome Atlas Research Network</collab><article-title>Comprehensive molecular characterization of gastric adenocarcinoma</article-title><source>Nature</source><volume>513</volume><fpage>202</fpage><lpage>209</lpage><year>2014</year><pub-id pub-id-type="doi">10.1038/nature13480</pub-id><pub-id pub-id-type="pmid">25079317</pub-id></element-citation></ref>
<ref id="b100-ol-33-1-15940"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristescu</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Nebozhyn</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>KM</given-names></name><name><surname>Ting</surname><given-names>JC</given-names></name><name><surname>Wong</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yue</surname><given-names>YG</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes</article-title><source>Nat Med</source><volume>21</volume><fpage>449</fpage><lpage>456</lpage><year>2015</year><pub-id pub-id-type="doi">10.1038/nm.3850</pub-id><pub-id pub-id-type="pmid">25894828</pub-id></element-citation></ref>
<ref id="b101-ol-33-1-15940"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>D</given-names></name><name><surname>Jansen</surname><given-names>M</given-names></name><name><surname>Gotoda</surname><given-names>T</given-names></name><name><surname>Coda</surname><given-names>S</given-names></name><name><surname>di Pietro</surname><given-names>M</given-names></name><name><surname>Uedo</surname><given-names>N</given-names></name><name><surname>Bhandari</surname><given-names>P</given-names></name><name><surname>Pritchard</surname><given-names>DM</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>British society of gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma</article-title><source>Gut</source><volume>68</volume><fpage>1545</fpage><lpage>1575</lpage><year>2019</year><pub-id pub-id-type="doi">10.1136/gutjnl-2018-318126</pub-id><pub-id pub-id-type="pmid">31278206</pub-id></element-citation></ref>
<ref id="b102-ol-33-1-15940"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>JK</given-names></name></person-group><article-title>Diagnosis and management of gastric dysplasia</article-title><source>Korean J Intern Med</source><volume>31</volume><fpage>201</fpage><lpage>209</lpage><year>2016</year><pub-id pub-id-type="doi">10.3904/kjim.2016.021</pub-id><pub-id pub-id-type="pmid">26932397</pub-id></element-citation></ref>
<ref id="b103-ol-33-1-15940"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>QY</given-names></name></person-group><article-title>Stratified management of residual gastric cancer risk after <italic>Helicobacter pylori</italic> eradication</article-title><source>Front Microbiol</source><volume>17</volume><fpage>1779490</fpage><year>2026</year><pub-id pub-id-type="doi">10.3389/fmicb.2026.1779490</pub-id><pub-id pub-id-type="pmid">41767558</pub-id></element-citation></ref>
<ref id="b104-ol-33-1-15940"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Advances in <italic>Helicobacter pylori</italic>-mediated oncogenic signaling pathways in gastric cancer: From pathological evolution to clinical application prospects (Review)</article-title><source>Oncol Lett</source><volume>32</volume><fpage>408</fpage><year>2026</year><pub-id pub-id-type="doi">10.3892/ol.2026.15763</pub-id><pub-id pub-id-type="pmid">42500607</pub-id></element-citation></ref>
<ref id="b105-ol-33-1-15940"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review)</article-title><source>Oncol Lett</source><volume>31</volume><fpage>108</fpage><year>2026</year><pub-id pub-id-type="doi">10.3892/ol.2026.15461</pub-id><pub-id pub-id-type="pmid">41586025</pub-id></element-citation></ref>
<ref id="b106-ol-33-1-15940"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moncada</surname><given-names>R</given-names></name><name><surname>Barkley</surname><given-names>D</given-names></name><name><surname>Wagner</surname><given-names>F</given-names></name><name><surname>Chiodin</surname><given-names>M</given-names></name><name><surname>Devlin</surname><given-names>JC</given-names></name><name><surname>Baron</surname><given-names>M</given-names></name><name><surname>Hajdu</surname><given-names>CH</given-names></name><name><surname>Simeone</surname><given-names>DM</given-names></name><name><surname>Yanai</surname><given-names>I</given-names></name></person-group><article-title>Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas</article-title><source>Nat Biotechnol</source><volume>38</volume><fpage>333</fpage><lpage>342</lpage><year>2020</year><pub-id pub-id-type="doi">10.1038/s41587-020-00776-5</pub-id><pub-id pub-id-type="pmid">31932730</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ol-33-1-15940" position="float">
<label>Figure 1.</label>
<caption><p>Competing trajectories of gastric tissue recovery and residual risk after eradication. The dominant pathway emphasizes established eradication-associated risk reduction followed by heterogeneous tissue recovery. Solid arrows denote directly observed post-eradication changes or established structural associations; dashed arrows denote candidate or unresolved relationships that require longitudinal validation. Dotted connectors indicate baseline pathological modifiers. Studies (<xref rid="b13-ol-33-1-15940" ref-type="bibr">13</xref>,<xref rid="b14-ol-33-1-15940" ref-type="bibr">14</xref>,<xref rid="b19-ol-33-1-15940" ref-type="bibr">19</xref>&#x2013;<xref rid="b24-ol-33-1-15940" ref-type="bibr">24</xref>) address eradication-associated risk reduction and residual risk. Overall and metachronous risk reduction is supported by certain studies (<xref rid="b14-ol-33-1-15940" ref-type="bibr">14</xref>,<xref rid="b19-ol-33-1-15940" ref-type="bibr">19</xref>&#x2013;<xref rid="b23-ol-33-1-15940" ref-type="bibr">23</xref>), whereas earlier analyses questioned the benefit once intestinal metaplasia or dysplasia was established (<xref rid="b13-ol-33-1-15940" ref-type="bibr">13</xref>,<xref rid="b24-ol-33-1-15940" ref-type="bibr">24</xref>). Paired or longitudinal immune and molecular trajectories are represented by certain studies (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>,<xref rid="b54-ol-33-1-15940" ref-type="bibr">54</xref>,<xref rid="b76-ol-33-1-15940" ref-type="bibr">76</xref>), as well as structural trajectories (<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>,<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>), microbial trajectories (<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>,<xref rid="b36-ol-33-1-15940" ref-type="bibr">36</xref>) and direct post-eradication stromal/immune-associated remodeling in chronic atrophic gastritis (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>). <italic>H. pylori, Helicobacter pylori</italic>; OLGIM, Operative Link on Gastric Intestinal Metaplasia Assessment; Me, methyl group.</p></caption>
<alt-text>Competing trajectories of gastric tissue recovery and residual risk after eradication. The dominant pathway emphasizes established eradication-associated risk reduction followed...</alt-text>
<graphic xlink:href="ol-33-01-15940-g00.tif"/>
</fig>
<fig id="f2-ol-33-1-15940" position="float">
<label>Figure 2.</label>
<caption><p>Tissue context of infection-associated remodeling and candidate persistence after eradication. The visually dominant left-to-right pathway separates evidence-supported observations from relationships that still require longitudinal validation. (A) The infection/precursor-stage layer summarizes epithelial metaplasia, myeloid and antigen-presentation programs, altered T-cell states and gastric tissue-resident memory T-cell biology (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>,<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>&#x2013;<xref rid="b64-ol-33-1-15940" ref-type="bibr">64</xref>,<xref rid="b69-ol-33-1-15940" ref-type="bibr">69</xref>&#x2013;<xref rid="b75-ol-33-1-15940" ref-type="bibr">75</xref>,<xref rid="b90-ol-33-1-15940" ref-type="bibr">90</xref>,<xref rid="b91-ol-33-1-15940" ref-type="bibr">91</xref>). Reference 64 demonstrates a resident-memory CD8&#x002B; T-cell cluster in a single <italic>ex vivo</italic> human gastric intestinal metaplasia biopsy and should not be interpreted as evidence of post-eradication persistence. (B) The candidate layer addresses whether such tissue states persist within the same individuals, remain functionally abnormal and predict outcomes independently of structural and epithelial-field burden. The localized immune-stromal interactions depicted in panel B represent tumor-stage mechanistic analogies rather than direct evidence of post-eradication stromal remodeling in gastric precursor mucosa (<xref rid="b80-ol-33-1-15940" ref-type="bibr">80</xref>&#x2013;<xref rid="b82-ol-33-1-15940" ref-type="bibr">82</xref>). Solid connectors denote evidence-supported associations; dashed connectors denote indirect, candidate or hypothesis-level links. APC, antigen-presenting cell; <italic>H. pylori, Helicobacter pylori</italic>; ECM, extracellular matrix.</p></caption>
<alt-text>Tissue context of infection-associated remodeling and candidate persistence after eradication. The visually dominant left-to-right pathway separates evidence-supported...</alt-text>
<graphic xlink:href="ol-33-01-15940-g01.tiff"/>
</fig>
<fig id="f3-ol-33-1-15940" position="float">
<label>Figure 3.</label>
<caption><p>Longitudinal study pathway for evaluating post-eradication mucosal immune trajectories. The main pathway visually prioritizes baseline assessment, confirmation of eradication, anatomically standardized paired tissue, follow-up and clinical outcomes. Solid connectors denote required measurements or evidence-supported analytical steps; dashed connectors denote hypothesized biological links that remain to be validated. Biological support requires exposure linkage, localization, persistence and functional evidence, or a proxy validated against immune function. Clinical translation additionally requires independent outcome association, external validation, calibration, incremental value and a meaningful effect on surveillance decisions (<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>,<xref rid="b66-ol-33-1-15940" ref-type="bibr">66</xref>). A signal that fails at either stage should remain a research observation rather than a clinical risk marker. <italic>H. pylori, Helicobacter pylori</italic>.</p></caption>
<alt-text>Longitudinal study pathway for evaluating post-eradication mucosal immune trajectories. The main pathway visually prioritizes baseline assessment, confirmation of eradication,...</alt-text>
<graphic xlink:href="ol-33-01-15940-g02.tiff"/>
</fig>
<table-wrap id="tI-ol-33-1-15940" position="float">
<label>Table I.</label>
<caption><p>Current human evidence: Supported vs. unproven.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Evidence category</th>
<th align="center" valign="bottom">Supports</th>
<th align="center" valign="bottom">Unproven</th>
<th align="center" valign="bottom">Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Residual-risk premise</td>
<td align="left" valign="top">Eradication reduces risk but does not eliminate it.</td>
<td align="left" valign="top">A specific immune mechanism or clinically useful biomarker.</td>
<td align="left" valign="top">Trials and syntheses of eradicationeffects, including conflicting findings in patients with advanced precursor lesions (<xref rid="b13-ol-33-1-15940" ref-type="bibr">13</xref>,<xref rid="b14-ol-33-1-15940" ref-type="bibr">14</xref>,<xref rid="b19-ol-33-1-15940" ref-type="bibr">19</xref>&#x2013;<xref rid="b24-ol-33-1-15940" ref-type="bibr">24</xref>), interpreted alongside current guidelines and structural-risk frameworks (<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>&#x2013;<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>).</td>
</tr>
<tr>
<td align="left" valign="top">Direct evidence from infected or precursor tissue</td>
<td align="left" valign="top">Measurable immune, epithelial and spatial heterogeneity during infection or precursor-stage disease.</td>
<td align="left" valign="top">Persistence after eradication or clinical utility.</td>
<td align="left" valign="top">Infection-associated immune differences (<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>,<xref rid="b69-ol-33-1-15940" ref-type="bibr">69</xref>); epithelial, spatial and immune-cell heterogeneity across infected mucosa and precursor lesions (<xref rid="b62-ol-33-1-15940" ref-type="bibr">62</xref>,<xref rid="b70-ol-33-1-15940" ref-type="bibr">70</xref>&#x2013;<xref rid="b75-ol-33-1-15940" ref-type="bibr">75</xref>); gastric TRM biology during <italic>H. pylori</italic> infection and experimental eradication/reinfection (<xref rid="b63-ol-33-1-15940" ref-type="bibr">63</xref>,<xref rid="b90-ol-33-1-15940" ref-type="bibr">90</xref>,<xref rid="b91-ol-33-1-15940" ref-type="bibr">91</xref>); a resident-memory CD8<sup>&#x002B;</sup> T-cell cluster identified in a single <italic>ex vivo</italic> human gastric intestinal metaplasia biopsy (<xref rid="b64-ol-33-1-15940" ref-type="bibr">64</xref>); and clonal and methylation fields within intestinal metaplasia (<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>).</td>
</tr>
<tr>
<td align="left" valign="top">Human evidence relevant to recovery after eradication</td>
<td align="left" valign="top">Reversibility of selected T-cell responses, together with heterogeneous molecular, structural, microbial and stromal recovery; the closest available outcome-linked immune evidence comes from post-resection CD8-associated trajectories.</td>
<td align="left" valign="top">A persistent, functionally defined immune state or a clinically useful immune marker in a primary-prevention population.</td>
<td align="left" valign="top">Functional T-cell reversibility (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>); outcome-linked CD8-associated trajectories after prior neoplasia (<xref rid="b54-ol-33-1-15940" ref-type="bibr">54</xref>); molecular response (<xref rid="b76-ol-33-1-15940" ref-type="bibr">76</xref>); structural trajectories (<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>,<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>); microbiome trajectories (<xref rid="b35-ol-33-1-15940" ref-type="bibr">35</xref>,<xref rid="b36-ol-33-1-15940" ref-type="bibr">36</xref>); and direct post-eradication stromal/immune-associated remodeling in chronic atrophic gastritis (<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>).</td>
</tr>
<tr>
<td align="left" valign="top">Indirect mechanistic evidence</td>
<td align="left" valign="top">Biological plausibility for myeloid-stromal and immune-epithelial interactions.</td>
<td align="left" valign="top">Direct causality in gastric mucosa containing precursor lesions.</td>
<td align="left" valign="top">Selected studies of gastric cancer and metaplasia models, together with one methodological precedent for spatial analysis (<xref rid="b47-ol-33-1-15940" ref-type="bibr">47</xref>,<xref rid="b48-ol-33-1-15940" ref-type="bibr">48</xref>,<xref rid="b77-ol-33-1-15940" ref-type="bibr">77</xref>,<xref rid="b80-ol-33-1-15940" ref-type="bibr">80</xref>&#x2013;<xref rid="b82-ol-33-1-15940" ref-type="bibr">82</xref>,<xref rid="b92-ol-33-1-15940" ref-type="bibr">92</xref>&#x2013;<xref rid="b96-ol-33-1-15940" ref-type="bibr">96</xref>,<xref rid="b106-ol-33-1-15940" ref-type="bibr">106</xref>).</td>
</tr>
<tr>
<td align="left" valign="top">Decisive human evidence not yet available</td>
<td align="left" valign="top">Post-eradication immune persistence and function, independence from morphology and epithelial-field burden, prospective outcome association and added clinical value in the intended prevention population.</td>
<td align="left" valign="top">The current cross-study evidence cannot support this integrated inference.</td>
<td align="left" valign="top">A prospective multicenter paired longitudinal cohort in which all decisive elements are measured in the same participants.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-ol-33-1-15940"><p>Evidence is graded by directness to the proposition being evaluated rather than by technological sophistication. H. pylori, Helicobacter pylori; TRM, tissue-resident memory T-cell; CD8, cluster of differentiation 8.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-ol-33-1-15940" position="float">
<label>Table II.</label>
<caption><p>Criteria for biological support and clinical utility.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom" colspan="3">A, Biological support</th>
</tr>
<tr>
<th align="left" valign="bottom" colspan="3"><hr/></th>
</tr>
<tr>
<th align="left" valign="bottom">Required criterion</th>
<th align="center" valign="bottom">Operational question</th>
<th align="center" valign="bottom">Minimum evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Exposure dependence</td>
<td align="left" valign="top">Can the state be linked to active or previous <italic>H. pylori</italic> exposure?</td>
<td align="left" valign="top">Documented exposure history combined with tissue measurement (<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>,<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>).</td>
</tr>
<tr>
<td align="left" valign="top">Tissue localization</td>
<td align="left" valign="top">Is the state localized to gastric mucosa containing a precursor lesion or to its surrounding field?</td>
<td align="left" valign="top">Standardized antrum/corpus mapping with spatial or multiplex assessment (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b26-ol-33-1-15940" ref-type="bibr">26</xref>,<xref rid="b27-ol-33-1-15940" ref-type="bibr">27</xref>,<xref rid="b62-ol-33-1-15940" ref-type="bibr">62</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Persistence</td>
<td align="left" valign="top">Is the feature reproduced at prespecified intervals after confirmed eradication?</td>
<td align="left" valign="top">Standardized paired sampling at empirically justified intervals sufficient to test persistence; no interval should be treated as a biological threshold (<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>,<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>,<xref rid="b76-ol-33-1-15940" ref-type="bibr">76</xref>).</td>
</tr>
<tr>
<td align="left" valign="top">Functional relevance</td>
<td align="left" valign="top">Does the feature alter antigen presentation, myeloid activity, T-cell surveillance or tissue organization?</td>
<td align="left" valign="top">A direct functional assay is preferred. Pathway-level or spatial evidence must be validated against functional immune activity; abundance alone is insufficient (<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>,<xref rid="b61-ol-33-1-15940" ref-type="bibr">61</xref>,<xref rid="b63-ol-33-1-15940" ref-type="bibr">63</xref>,<xref rid="b91-ol-33-1-15940" ref-type="bibr">91</xref>).</td>
</tr>
<tr>
<td align="left" valign="top" colspan="3"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" colspan="3"><bold>B, Clinical utility</bold></td>
</tr>
<tr>
<td align="left" valign="top" colspan="3"><hr/></td>
</tr>
<tr>
<td align="left" valign="top"><bold>Required criterion</bold></td>
<td align="center" valign="top"><bold>Operational question</bold></td>
<td align="center" valign="top"><bold>Minimum evidence</bold></td>
</tr>
<tr>
<td align="left" valign="top" colspan="3"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Independent outcome association</td>
<td align="left" valign="top">Does the feature predict incident dysplasia or gastric cancer after established covariates have been included?</td>
<td align="left" valign="top">Prospective association with prespecified, stage-appropriate outcomes in the population in which persistence and competing tissue fields are measured (<xref rid="b12-ol-33-1-15940" ref-type="bibr">12</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b54-ol-33-1-15940" ref-type="bibr">54</xref>,<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>).</td>
</tr>
<tr>
<td align="left" valign="top">External validation and clinical utility</td>
<td align="left" valign="top">Does a prespecified assay remain well calibrated and improve surveillance decisions in independent cohorts?</td>
<td align="left" valign="top">External validation, adequate calibration, transparent reporting and clinically meaningful incremental value, consistent with established biomarker and prediction-model principles (<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>,<xref rid="b66-ol-33-1-15940" ref-type="bibr">66</xref>).</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn2-ol-33-1-15940"><p><italic>H. pylori, Helicobacter pylori</italic>.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tIII-ol-33-1-15940" position="float">
<label>Table III.</label>
<caption><p>Alternative explanations and discriminating tests.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Model</th>
<th align="center" valign="bottom">Proposed mechanism</th>
<th align="center" valign="bottom">Expected observation</th>
<th align="center" valign="bottom">Discriminating test</th>
<th align="center" valign="bottom">(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Persistent metaplastic burden</td>
<td align="left" valign="top">Irreversible or slowly reversible glandular architecture carries residual risk.</td>
<td align="left" valign="top">Risk follows the extent, subtype and distribution of atrophy or metaplasia.</td>
<td align="left" valign="top">Adjust for OLGIM/EGGIM, metaplasia extent and subtype, and repeated histology.</td>
<td align="center" valign="top">(<xref rid="b15-ol-33-1-15940" ref-type="bibr">15</xref>,<xref rid="b16-ol-33-1-15940" ref-type="bibr">16</xref>,<xref rid="b25-ol-33-1-15940" ref-type="bibr">25</xref>,<xref rid="b26-ol-33-1-15940" ref-type="bibr">26</xref>,<xref rid="b30-ol-33-1-15940" ref-type="bibr">30</xref>,<xref rid="b31-ol-33-1-15940" ref-type="bibr">31</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Epithelial clonal/epigenetic field</td>
<td align="left" valign="top">Clonal and methylation fields within intestinal metaplasia provide a competing epithelial explanation; their persistence specifically after eradication remains unproven.</td>
<td align="left" valign="top">Epithelial-field measures attenuate or outweigh the outcome association attributed to immune features.</td>
<td align="left" valign="top">Quantify a minimum structural field comprising OLGIM stage, metaplasia extent/distribution and subtype; incorporate EGGIM where available; and, in molecularly profiled cohorts, prespecify a quantitative methylation or clonal/mutational-burden measure. Test whether candidate immune features retain independent and incremental outcome information beyond these variables.</td>
<td align="center" valign="top">(<xref rid="b56-ol-33-1-15940" ref-type="bibr">56</xref>,<xref rid="b57-ol-33-1-15940" ref-type="bibr">57</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Occult infection or reinfection</td>
<td align="left" valign="top">Continued microbial stimulation sustains inflammation.</td>
<td align="left" valign="top">Persistent features disappear when infection is excluded rigorously.</td>
<td align="left" valign="top">Use multiple tests of eradication, longitudinal microbiology and sensitivity analyses.</td>
<td align="center" valign="top">(<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b29-ol-33-1-15940" ref-type="bibr">29</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Microbiome or exposure modifier</td>
<td align="left" valign="top">Non-<italic>H. pylori</italic> microbiota, diet and medication-related effects on infection ascertainment or microbial measurement alter the observed tissue state.</td>
<td align="left" valign="top">Associations vary with geography, eradication status, medication exposure or diet.</td>
<td align="left" valign="top">Standardize exposure measurement, document antibiotic use and acid suppression, and test replication across geographic settings (<xref rid="b8-ol-33-1-15940" ref-type="bibr">8</xref>,<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b34-ol-33-1-15940" ref-type="bibr">34</xref>&#x2013;<xref rid="b39-ol-33-1-15940" ref-type="bibr">39</xref>)</td>
<td align="center" valign="top">(<xref rid="b8-ol-33-1-15940" ref-type="bibr">8</xref>,<xref rid="b11-ol-33-1-15940" ref-type="bibr">11</xref>,<xref rid="b17-ol-33-1-15940" ref-type="bibr">17</xref>,<xref rid="b34-ol-33-1-15940" ref-type="bibr">34</xref>&#x2013;<xref rid="b39-ol-33-1-15940" ref-type="bibr">39</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Candidate immune-associated persistence</td>
<td align="left" valign="top">A localized functional state, or a functionally validated proxy, remains after eradication and contributes to risk.</td>
<td align="left" valign="top">Immune features persist after eradication and add outcome information beyond competing models.</td>
<td align="left" valign="top">Use paired functional, pathway-level or validated spatial assessment; compare competing models; validate externally; and demonstrate clinically meaningful incremental value.</td>
<td align="center" valign="top">(<xref rid="b53-ol-33-1-15940" ref-type="bibr">53</xref>&#x2013;<xref rid="b55-ol-33-1-15940" ref-type="bibr">55</xref>,<xref rid="b59-ol-33-1-15940" ref-type="bibr">59</xref>,<xref rid="b60-ol-33-1-15940" ref-type="bibr">60</xref>,<xref rid="b65-ol-33-1-15940" ref-type="bibr">65</xref>,<xref rid="b66-ol-33-1-15940" ref-type="bibr">66</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn3-ol-33-1-15940"><p>EGGIM, Endoscopic Grading of Gastric Intestinal Metaplasia; H. pylori, Helicobacter pylori; OLGIM, Operative Link on Gastric Intestinal Metaplasia Assessment.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
